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Diploid organisms inherit one set of genes from their mother and one from their father.
The expression of a subset of these genes however depends on which parent they were 
inherited from. This is known as genomic imprinting. Mendelian inheritance is when both 
alleles in a heterozygote organism are equally expressed. Imprinted genes do not follow the 
rule of Mendelian expression. Many organisms have a type of imprinting mechanism 
ranging from unicellular organisms (Matagne 1987), arthropods (Spofford 1976), 
mammals (Efstratiadis 1994) and angiosperms (Matzke 1993). In 2001 Reik et al. carried 
out experiments in which mouse embryos were created, in which both sets of chromosomes 
originated from parents of the same sex, showed differences in phenotype depending on 
whether the chromosomes came from the male or female (Reik 2001). Genomic 
imprinting was discovered in the early nineties by creating mouse uniparental embryos and 
mouse embryos which had uniparental disomys (Cattanach 1985). Nuclear transplantation 
was used to create embryos that inherited chromosomes from one parent only. In the 
embryos that had two paternal sets of chromosomes (androgenetic) it was noted that the 
extraembryonic tissues such as the placenta were well developed but the embryo itself was 
not. In embryos that had two maternal sets of chromosomes (parthenogenetic or 
gynogenetic) it was noted that the embryo was well developed but the extraembryonic 
tissues were not. This is discussed more fully later (Section 1.2.). About 50 mammalian- 
imprinted genes have been identified (www.mgu.har.mrc.ac.uk) and it is estimated that the 
mouse genome may contain about 100 imprinted genes in total. Although imprinted genes 
are often referred to as being ‘active’ or ‘silent’ there is often some detectable RNA from 
the so called ‘silent’ allele. If the expression ratio of one allele to the other is less than 3:1 
or greater it can be considered to be an imprinted gene (Bums 2001). In the case of Igf2 
RNA expression from the ‘silent’ maternal allele is around 10% that from the paternal 
allele in the embryo apart from the biallelic expression in the leptomeninges (DeChiara 
1991).
Later it was found that epigenetic marks on the genome differentiated the egg and sperm 
DNA leading to differential gene expression known as imprinting. Most known 
mammalian imprinted genes (80%) tend to be clustered and contain epigenetic markings. 
Epigenetic marks differentiate the maternal from the paternal allele without altering the
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nucleotide sequence and are discussed more fully in Section 1.7. Many imprinted genes 
are found close to another, oppositely imprinted gene such as Igf2 and HI 9 on mouse 
chromosome 7, Dlkl and Gtl2 on mouse chromosome 12. Groups of functionally related 
genes such as the Hox genes that arise by gene duplication events are often grouped 
together (Von Mering 2002). In nematodes, it has been observed that co-regulated genes 
are sometimes organised into regulatory units called operons. This clustering of imprinted 
genes may make it easier for c/s-regulatory elements to control the imprinting of a number 
of genes within a cluster (Caspary 1999). However non-imprinted genes are also clustered 
and so this cannot be regarded as a defining feature of imprinted genes. The clustered 
genes may have areas of differential methylation or histone acetylation between the 
maternal and paternal allele, and may also have replication timing differences and 
chromatin structure differences (Brannan 1999) . Methylated DNA typically generates 
inactive chromatin structure and this can spread to neighbouring unmethylated DNA 
exerting its silencing effect over a larger portion of the chromosome. This mechanism of 
controlling gene expression may be one reason to cluster imprinted genes (Hu 2000).
Imprinted genes are usually rich in CpG islands, which are defined as a 200bp 
region of DNA with a G+C content of over 50%. Analysis of the mouse genome found that 
47% of mouse genes are associated with CpG islands but this frequency increases to about 
88% when mouse imprinted genes are examined. Direct sequence repeats are also found 
near to these CpG islands (Paulsen 2000). About 10% of the genome consists of repetitive 
DNA sequences mostly located in heterochromatic regions around the centromeres and 
telomeres. Mutations in these repeat sequences are associated with haemophilia and 
cancers of the breast and colon.
To imprint a gene epigenetic marks must be established. Imprinting marks are 
established in the sperm and egg and are maintained after fertilisation and throughout 
development (Table 1). Imprinting requires that the marks must be erased and reset 
correctly in the germ cells of the next generation. This erasure is associated with a genome 
wide demethylation of the DNA, which is completed by embryonic day 12-13 (El 2-13) in 
the mouse. Then de novo methylation occurs with methyltransferase from the Dnmt genes 
re-establishing the imprint.
In mice lacking the Dnmtl gene Igf2 is no longer expressed (Li, Beard et al. 1993) 
showing the importance of methylation in the control of expression of Igf2 (Section 1.6.1).
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However, a notable exception is the Mash2 gene that’s imprinted expression remains in 
Dnmtl knockout embryos (Dell 1997).
Other genes affected by a lack of methyltransferase are the Xist gene leading to 
partial inactivation of one of the X-chromosomes in females (Beard 1995), H19 is 
biallelically expressed and maternal Igf2r is silenced (Li, Beard et al. 1993).
1.2 Evolution of imprinting.
There are many theories to explain the existence of imprinted genes. Large 
proportions of imprinted genes are associated with fetal growth or cell proliferation. One 
theory is that the paternally expressed genes are in competition with the maternally 
expressed genes. The paternally expressed genes tend to act selfishly and opportunistically, 
with the aim of utilising maternal resources as they can so that the offspring will develop to 
be as fit as possible, even if this occurs at the expense of the other siblings (parent 
offspring conflict hypothesis)(Moore 1991).
The maternally expressed genes aim to reduce this competition between siblings by 
trying to allocate all of maternal resources equally but not to the extent as to endanger the 
future reproductive fitness of the mother (Moore 1991). Postnatally the competition effects 
of imprinted genes can also be observed. Mice with paternal disomys have been observed 
to be hyperkinetic and those with a maternal disomy were observed to be hypokinetic 
(Cattanach 1985). Female mice with a deficiency in the paternally expressed Mest gene 
shown abnormal maternal behaviour. These mice do not respond as normal to their 
newborn pups with 84% of litters having at least one unattended pup. Half of the pups were 
not properly cleaned after birth and were not fed properly. This implies a paternal control 
over the distribution of maternal resources not only during embryogenesis but postnatally 
also .
Experimental evidence from mice shows that in an androgenetic embryo, the 
embryo itself is underdeveloped and the extraembryonic membranes are well developed. 
Parthenogenetic embryos on the other hand have a well-developed embryo and the 
extraembryonic membranes are underdeveloped. These membranes (placenta) divert 
maternal resources to the relevant foetus at the possible expense of the other fetuses 
(Moore 1991). Two examples of genes that demonstrate the different priorities of the 
maternal and paternal genes are GrblO and Ig/2. GrblO is a maternally expressed
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imprinted gene. Disruption of this gene in mice leads to a 30% increase in size of the 
embryo and the placenta (Charalambous 2003). Without the maternal allele to keep the 
growth rate in check the embryos are larger. Igf2 is a paternally expressed imprinted gene. 
Disruption of this gene leads to a 30% reduction in the size of the embryo (DeChiara 
1990). Without the paternal allele to allocate maternal resources to the embryos the mice 
are smaller.
This theory fits in very well with organisms that are polyandrous. It can be applied 
both when different litters have different fathers and also when different fetuses within a 
litter have different fathers. However, imprinted genes have been found in monogamous 
species such as P. polionotus where they should not be necessary according to this theory. 
Nevertheless, it has been argued that such species may have evolved from polyandrous 
ancestors and that if the male dies the female will mate with another male and this may be 
sufficient to retain the imprinting mechanism.
Arguing against the parent offspring conflict hypothesis is X chromosome 
inactivation. This can occur in two ways, either the paternal X chromosome is inactivated 
(as occurs in the trophectoderm and primitive endoderm) or the X chromosome is 
randomly inactivated (as occurs in somatic tissues of female eutherians) (Moore 1991). It 
could be argued that it would be more beneficial to the paternally derived genes if all of 
them were active in the placenta. Also imprinting would be expected in somatic tissues and 
yet X chromosome inactivation is random.
Another theory regarding the existence of imprinting is that it works as a defence 
mechanism. It is thought to prevent the production of parthenogenic offspring that in the 
long term have a higher chance of becoming extinct and so are not beneficial to the total 
population. Since imprinting makes parthenogenic offspring non-viable it allows the 
mother to reallocate her resources to viable offspring (sexually produced). The 
parthenogenic offspring are aborted relatively early, in order to conserve maternal 
resources. However, this theory cannot explain the differential paternal and maternal 
control of embryonic growth. Nor can it explain why paternal genes are also imprinted. 
Thomas (Thomas 1995) theorised that imprinting was a defence mechanism against 
aneuploidy but the effects of aneuploidy tend to manifest as abortion relatively late in 
gestation. As mentioned before, an imprinting advantage would be to abort defective 
offspring before much maternal resources have been utilised.
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Thomas also (Thomas 1995) conceived a theory that imprinting could be a surveillance 
mechanism for chromosome loss. This suggests that if imprinted genes were found 
throughout the entire genome that they could be used as a sort of early warning system for 
partial or total chromosome loss or gain. This is because if some or all of a chromosome is 
lost then the organism will have lost expression of the only expressed allele of a gene 
instead of one of the pair of expressed alleles in the case of most genes which makes it 
easier for the cells to detect the loss. This could benefit the organism in two ways, first by 
protecting the organism from cancer and also by enabling early detection of fetal 
chromosome imbalances.
A further theory suggested by Varmuza and Mann (Varmuza 1993) is that 
imprinting protects the mother from trophoblast tumours. Since the trophoblast does not 
develop well from parthenogenic embryos, the mother is protected from potentially 
invasive trophoblast-like tumours. However again the theory does not explain paternal 
silencing. Also angiosperm plants do not have an invasive trophoblast but still have also 
evolved an imprinting mechanism so the theory is not sufficient in this regard.
If a cell used the total loss of expression of an imprinted gene as an indication of 
partial or total chromosome loss then cells from the immune system may require the 
proteins from the imprinted gene to be expressed to allow the cell to live. Without these 
gene products the cell would fail to pass the immune systems checkpoint and could be 
eliminated. Alternatively, the imprinted genes could be required for cell division so that 
when lost the cell is unable to divide and again is eliminated. However, it has been difficult 
to find evidence to support this theory, as imprinted genes would need to be present on 
every chromosome and for every one to have a strong deleterious effect if lost.
In summary, it is obvious that each theory does have some merit, but none are 
sufficient to explain the existence of imprinting in the genome. Currently the most popular 
theory is the parent offspring conflict hypothesis, which has the most evidence to support 
it.
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1.3: Imprinting disease, growth disorders and cancer.
1.3.1 Disease and growth disorders
The expression of Igf2 has an important role in the rare overgrowth disorder 
Beckwith-wiedemann syndrome (BWS) (Wiedemann 1983), (Dell 1997). BWS is a 
congenital overgrowth syndrome characterised by somatic overgrowth, macroglossia, 
abdominal wall defects and a susceptibility to childhood tumours especially Wilms tumour 
of the kidney (Wiedemann 1983). Both Igf2 and another imprinted gene called p57^P^  are 
associated with BWS. p57^P^ is maternally expressed and codes for a cyclin-dependent 
kinase (CDK) inhibitor (CKI) (Bourcigaux 2000). Both of these genes are expressed in all 
the tissues affected by BWS (Lee, Pintar et al. 1990) and it is thought that a loss of 
imprinting of Igf2 leading to the activation of the normally silent maternal allele, and the 
loss of function of p57^-P^ can cause BWS (Table 1). Loss of function of maternal p57^P^ 
was observed in 5-10% of sporadic (non-familial) cases of BWS that occur (Hatada I.
1996).
IGF2 expression levels were higher than normal in some, but not all patients with 
BWS (Weksberg 1993). Disruption of Igf2 imprinting results in mice displaying some of 
the symptoms of BWS, but not all (DeChiara 1990). Equally over expression of Igf2 does 
not demonstrate the full BWS phenotype fully either (Leighton 1995). Chimeras have been 
made from embryonic stem cells containing an Ig fl transgene. These animals over­
expressed Ig/2 and showed some of the features of BWS during development [Sun F., 1997 
#65].
Igf2r is located on mouse chromosome 17 and is also imprinted. It is maternally 
expressed starting at E6.5. Inheritance of a paternal mutant copy (null allele) of the gene 
had no phenotype whereas inheritance of a maternal mutant copy resulted in mice with 
cardiac abnormalities, a tail kink, increased levels of circulating Ig/2 and overgrowth (they 
were 30% larger than their siblings) (Lau M. 1994).
A paternal deletion of the 15ql 1-ql 3 human chromosome occurs in 60-70% of 
cases of Prader-Willi syndrome (PWS). This disease is characterised by hypogonadism, 
mental retardation, hypotonia and small hands and feet. This region was found to be 
imprinted when the disease Angelman syndrome (AS) was found to occur in patients with 
a maternal deletion of chromosome 15ql 1-ql 3. Angelman syndrome is characterised by 
mental retardation, a puppet-like ataxic gait, hyperactivity, seizures and hypotonia (Lalande
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1997). One or other of these disorders occurs 1 in 15,000 births with familial recurrences. 
These disorders occur as a result of breakpoints at particular regions of chromosome 
15ql 1-13. There are four genes in this region, which are possible candidates for these 
disorders, CYFIP1, GCP5, NIPA1 and NIPA2 .
Maternal uniparental disomy of the gene GrblO has been observed in 10% of 
human patients with the disease Silver-Russell syndrome (SRS). This disease results in 
growth retardation, congenital hemihypertrophy and craniofacial abnormalities.
(Wollmann 1995) (Table 1). Regions 7pll.2-pl3 and 7q31 have been associated with SRS 
as well as possible candidates on chromosome 17 .
1.3.2 Cancer
In patients with colorectal cancer hypomethylation of IGF2 DMR1 and the H 19 
DMR resulting in loss of imprinting (LOI) of this region (Table 1). This hypomethylation 
is found both in the tumours and in the non-cancerous mucosa of the same patients (Cui 
2002). This has been found in 30% of colorectal cancer patients and in only 10% of healthy 
patients. It has therefore been suggested that testing for LOI in this region can be used as 
an indication of the risk of developing colorectal cancer (Cui 2003). In mice in which the 
methylation gene Dnmtl had been mutated, reducing the level of methylation in the 
genome to 10%. These mice later (at around 6months of age) developed T cell lymphomas 
indicating that DNA methylation can play a role in tumour formation (Gaudet 2003).
Most Wilms’ tumours are not associated with BWS but usually exhibit loss of 
imprinting of Ig/2. With a large proportion of Wilms’ tumours in which loss of imprinting 
of Igf2 has been observed, silencing of the normally maternally expressed H19 gene (codes 
for an untranslated RNA) has also been identified (Moulton, Crenshaw et al. 1994). The 
Igf2 antisense transcript is also over expressed but only in some of the Wilms tumours 
examined (2 out of six tumours). In any tumours where Ig/2 imprinting was normal, Igf2 
antisense imprinting was also maintained (Vu 2003). In experiments carried out on 
Wilms’s tumour cell lines it was found that the addition of Igfl and Ig/2 resulted in 
apoptosis and necrosis of the tumour cells (Granerus 2001).
The Ig/2r gene is thought to have tumour supressor effects in humans. It inactivates 
Igf2 so loss of Igf2r increases cell proliferation and reduces cell apoptosis. LOH of Ig/2r 
was observed in 61% of patients with hepatocellular carcinoma (Yamada 1997).
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Examinations of human squamous cell carcinomas of the lung had a loss of heterozygosity 
(LOH) of Igf2r in 58% of cases (Kong F. 2000). (Table 1).
Indirect links between imprinting and cancer can be observed in other tumour 
types. Hydatidiform moles arise from androgenetic embryos and ovarian teratomas arise 
from parthogenetic embryos. Complete embryogenesis requires both the maternal and 
paternal genomes.
Region Mutation Result
Ig/2 LOI (biallelic expression) BWS, Colorectal cancer, 
Wilms tumours,
p57klP2 Loss of Function BWS
H19 LOI (HI9 silenced) Wilms tumours, 
Colorectal cancer.
GrblO mUPD SRS
Ig fir Maternal null allele Overgrowth (30%), cardiac 
abnormalities, tail kink.
Igf2r LOH Squamous cell carcinoma 
of the lung.
Mash2 Maternal null allele. Placental failure, 
embryonic lethal.
Maternal 15qll-ql3 Deletion AS







Table 1. Summary of epigenetic changes in imprinting regions and their resulting disorders.
The region refers to a gene or chromosome that was mutated. The mutation refers to what has been altered 
on the gene and the result refers to what disorder occurs when the gene is mutated in this way.
1.4 Insulin-like growth factor II gene
Insulin-like growth factor II (IGF2) is a fetal and postnatal growth factor found in 
mammals. The Igf2 gene encodes a single polypeptide, which is thought to have autocrine, 
paracrine and endocrine actions (Efstratiadis 1998). It is found on the distal portion of 
mouse chromosome seven and human chromosome eleven, region 1 l p l5.5 (131.7Mb) 
(Tricoli 1984). Igf2 has eight exons with multiple promoters and also different splice 
variants of transcripts. The IGF2 peptide is structurally and functionally related to the 
insulin hormone. IGF2 interacts with the insulin-like growth factor type one receptor 
(IGF1R), the type two receptor (IGF2R) and also the insulin receptor (INSR) with IGF2R 
having the highest affinity for IGF2. Igf2 is oppositely imprinted with respect to Igf2r with 
the paternal allele expressed and the maternal allele silenced at most sites of expression 
(DeChiara 1991). It is expressed in both mesodermal and endodermal tissues during mouse 
embryogenesis. Biallelic expression is known to occur in the choroid plexus and the 
leptomeninges of both embryonic and adult mice. Igf2 is first expressed in the 
trophectodermal derivatives immediately after implantation, and then is localised in the 
extraembryonic and embryonic mesoderm and the foregut lining (Lee, Pintar et al. 1990).
The role of Igf2 as a growth factor was demonstrated by generating mice that 
lacked a functional paternal copy of the gene. The mutated mice were only 60% of the size 
of their wild type littermates (DeChiara 1990). Their placentas were also in proportion to 
their body weights, which was in keeping with in situ hybridisation analysis showing that 
the components that form the chorioallantoic placenta express Igf2 (Lee, Pintar et al. 1990).
Mouse Igf2 (Figure 1.) has four promoters with promoter one (PI) driving 
expression in the placenta and promoters P2 to P4 both in the embryo and in placenta. 
Imprinted genes influence growth at the level of cell proliferation and apoptosis in the fetus 
but they can also influence growth by affecting the structure of the placenta and therefore 
the flow of nutrients to the fetus (Constancia M. 2002). PI transcripts are expressed in the 
labyrinthine trophoblast cells in the placenta and when PI was deleted this resulted in 
impaired growth when the deletion was paternally inherited. The mutant placentas were 
76% the size of wild-type placentas) (Constancia M. 2002). The resulting pups were at 
birth 69% of the size of wild type littermates but by the age of three months had caught up 
with their siblings. P2 transcripts are found in the liver and P3 and P4 transcripts are most 
abundant in the embryo during the latter stages of embryogenesis. There are three regions
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Igf2 gene H I9 gene
PI P2 P3 P4 H I9 promoter
h # 7f
Exons: 1 2 3 4 5 6 7 CCD H19
enhancers
DMRO DMR1 DMR2 DMD
Figure 1. Map of the Igf2-H19 region of mouse chromosome 7.
P1-P4 refers to the promoters found in Ig/2. The black lines(not to scale) show the areas o f differential methylation (DMR)and the ovals represent the H19 enhancers. The 
CCD is the centrally conserved domain found between /g/2 and H I 9.
of differential methylation, one ~3kb upstream from P2 (Differentially Methylated Region 
One, DMR1), another lies within exons 7 and 8 (DMR2) and DMRO lies further upstream 
of Ig/2. These are discussed in more detail in section 1.7.1.
1.5 H19 gene
The HI 9 gene is located about lOOkb downstream from Igf2 (Figurel) and it codes for an 
untranslated RNA. It may act as a tumour supressor through an unknown mechanism or 
may act solely to regulate Ig/2 expression. The H19 gene is oppositely imprinted to Igf2, 
the maternal allele is expressed and the paternal allele is silent. The expression pattern of 
HI 9 is very similar to the expression pattern of Ig/2 except in the choroid plexus and 
leptomeninges (Ohlsson 1994). In the stromal cells of the choroid plexus both HI 9 and 
Ig/2 are imprinted, but in the epithelial cells of the choroid plexus there is no expression of 
H19 and biallelic expression of Ig/2 (T. Menheniott, personal communication).
Deletion of maternal HI 9 activated the maternal Ig/2 gene and resulted in mice that 
were 130% of normal body weight at birth (Leighton 1995). The up regulation of maternal 
Ig/2 led to the development of the ‘enhancer competition model’ to explain the link 
between Ig/2 imprinting and H I9. The expression patterns and the opposing imprints 
indicated that the genes may have been competing for the H19 enhancers (Figure 1). On 
the unmethylated maternal allele there is nothing to prevent the 3’ enhancers up regulating 
the expression of HI 9. On the methylated paternal allele, the Ig/2 gene competes more 
efficiently for the H19 enhancers due to methylation of the HI 9 promoter and Ig/2 is 
therefore the gene expressed on the paternal allele. Experiments carried out on an 
unmethylated YAC containing the Ig/2/H19 gene cluster showed flaws in the competition 
model as just described above. It was expected that the YAC would behave as the maternal 
allele behaved (which is unmethylated in wild type Ig/2) and that Ig/2 would be silenced 
(as it is on the maternal allele) and H19 expressed. What actually resulted was expression 
from both of the genes (Webber 1998). This model was then further refined following the 
discovery of a methylation-sensitive boundary in the region between Ig/2 and H I9, which 
explains the results observed above (discussed in section 1.7.1.).
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1.6 Antisense transcripts
A deletion in the gene Igf2r resulted in LOI of the gene and also loss of expression 
of the antisense transcript. It was shown that this deletion included a promoter for a 
paternally expressed antisense transcript. When a truncated version of Igf2r antisense was 
maternally transmitted the mice were similar to wild type but a paternally transmitted 
truncated Igf2r antisense gene resulted in mice that were 15% smaller than their wild type 
littermates. This phenotype can be replicated in mice with biallelic expression of Igf2r 
(Sleutels 2002). When the sense transcript is expressed the antisense is not and when the 
antisense is expressed the sense is not (Reik 1997). This antisense transcript has been 
named Air and is thought to regulate the imprinting not just of Igf2r but also of the 
neighbouring imprinted genes Slc22a2 and Slc22a3 which are also maternally expressed 
(Sleutels 2002). Air overlaps the Igf2r promoter and codes for an untranslated RNA. When 
this was deleted on the paternal allele Slc22a2 and Slc22a3 are no longer silenced (Zwart 
2001).
Ig/2 has three anti sense transcripts called Ig/2as-a, Igf2 as-b and Ig/2 as-c. Ig/2as-b 
(Figure 2) is associated with promoter elements and has four exons and so is most likely of 
the three as transcripts to code for a functional RNA (Moore 1997).
The imprinted gene Gnas also has an antisense transcript, which starts in between 
promoters PI and P2. Gnas is on mouse chromosome 2 and codes for the a subunit of a 
nucleotide binding protein. Transcripts from the PI promoter are maternally expressed and 
transcripts from the P2 promoter are paternally expressed. Gnas antisense (Gnas-as) is 
expressed from the paternal allele like the P2 transcript from the paternal sense allele.
This is opposite to Ig/2 where the antisense transcript comes from the same paternal allele 
as the sense transcript. In the case of Ig/2r and Gnas the antisense transcript comes from 




Exons 1 2  3 4
DMRO DMR1
Antisense transcript {Igf2as-b)
Figure 2.Section of Igf2 gene and all of thelgf2 antisense transcript. (Moore 1997)
P1-P3 refers to some of the promoters found in Igf2. The black lines show two o f the three areas o f  
differential methylation. The black arrow shows where the antisense transcript lies and the direction o f  
transcription.
1.7. Epigenetic marks.
1.7.1 Methylation of Igf2 and H19.
Methylation is an epigenetic mark as it does not alter the nucleotide sequence but can be 
used to distinguish the paternal from the maternal allele. The methylation pattern of Igf2 is 
unusual as the expressed paternal allele is the more highly methylated allele. There are 
three regions of differential methylation associated with Ig/2.
The first, differentially methylated region 0 (DMRO) is associated with a placenta 
specific transcript and is located upstream from Igf2 (Figure 1). This region is maternally 
hypermethylated in the placenta. In the fetus both the maternal and paternal DMROs are 
equally methylated (Moore 1997).
The second region (DMR1) is 600bp long, is located within the 5’ portion 
of the Igf2 gene (Figure 1) and is paternally hypermethylated (Sasaki, Jones et al. 1992). 
DMR1 contains a methylation sensitive silencer. Deletion of DMR1 on the maternal allele 
results in expression of Igf2 in mesodermal tissues (Constancia 2000). In experiments 
carried out on DMR1 using bisulphide sequencing a mosaic pattern of methylation was 
found in a gradient across a CpG island consisting of thirteen CpGs. CpG 1 was found to 
be most frequently hypermethylated on the paternal allele whereas CpG 13 was found to be 
paternally hypermethylated with the lowest frequency. There was no CpG that was always
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maternally unmethylated and paternally methylated. CpGs 1 to 4 showed the greatest 
differences having almost twice the frequency of methylation paternally compared to 
maternally (Feil 1994).
The third DMR, DMR2, is located within the 3’ coding region of the Igf2 gene. 
DMR2 is paternally hypermethylated in specific tissues such as the foetal liver but is found 
to be hypomethylated in foetal brain and kidneys. DMR2 contains a methylation sensitive 
activator (Feil 1994). Deletion of DMR2 on the maternal allele has no effect on Ig/2 
expression and a deletion on the paternal allele leads to slightly retarded fetal growth 
(Murrell 2001).
The H19 gene located about lOOkb downstream of Igf2 also has a DMR. This DMR 
(ICR) about 7 to 9kb 5’ of the H19 coding region and is hypermethylated on the inactive 
paternal allele and hypomethylated on the active maternal allele (Bartolomei, Webber et al. 
1993). Deletion of the H19 DMR results in activation of maternal Igf2 (Leighton 1995).
The H19 DMR is methylated in sperm but not in oocytes and this is maintained throughout 
development (except in the germ cells). DMR1 and DMR2 are also methylated in sperm 
but not in oocytes but this methylation does not remain throughout development so it is 
thought that H I9 DMR is the primary germline modification involved in the regulation of 
Igf2/H19. Methylation is erased at the morula stage and re-established at post implantation. 
Deletion of the H19 DMR on the maternal allele increased methylation levels of DMR 1 
and DMR2, and deletion on the paternal allele had no effect (Table 2). Deletion of DMR1 
on the maternal allele increased methylation levels in DMR2 but had no effect on the H19 
DMR. A paternal deletion did not affect either. Deletion of DMR2 did not effect DMR1 or 
H19 DMR methylation. This suggests a hierarchy of DMRs working to establish and 
maintain the imprint within the Igf2/H19 gene cluster. When de novo methylation during 
embryogenesis occurs (Dnmt) the already methylated H I9 DMR protects maternal DMR1 
and DMR2 from methylation, as removal of H19 DMR results in maternal methylation of 




Paternal H19 DMR 
Maternal HI 9 DMR
No effect on DMR1 or DMR2. 




No effect on DMR2 or H I9 DMR. 
Increased methylation on DMR2, no effect 
on H I9 DMR.
Either paternal or maternal DMR2 No effect on DMR1 or H I9 DMR.
Table 2. Summary of methylation hierarchy.
This table summarises the effects deletions o f Igf2 DMRs and H19DMR has on the methylation o f the other 
DMR’s in the Igf2-H19 gene pair (Lopes 2003).
The way in which methylation controls the imprinting of Igf2 and H19 involves a 
DNA binding protein called CTCF. CTCF is a nuclear protein (CCCTC- binding factor) 
that binds to DNA via a zinc finger (Bell 1999). It can act as a gene activator, repressor, 
silencer or chromatin insulator by forming complexes with DNA, some of which are 
methylation sensitive (Ohlsson 1994). 90kb downstream of the Ig/2 gene lies the 
imprinting control region (ICR) (also referred to as the differentially methylated domain, 
DMD). The ICR is methylated on the paternal allele and is unmethylated on the maternal 
allele. CTCF cannot bind to methylated ICR allowing the H19 enhancers to upregulate the 
expression of Ig/2 on the paternal allele. CTCF can bind to unmethylated ICR, insulating 
Igf2 from the effect of the H I9 enhancers on the maternal allele (Figure 1) (Li, Beard et al.
1993) (Leighton 1995).
The silencer activity of the ICR can be seen in endodermal tissues where HI 9 
expression is switched off (Drewell 2000). When a deletion was made in this region and 
paternally transmitted, silencing was relaxed and the H19 gene was expressed with loss of 
Igf2 expression. Maternal deletion of the 1.2kb region had no effect on H I 9 expression. 
The expression of paternal H19 was restricted to tissues where the H19 enhancers have an 
effect. A second paternal deletion in the ICR led to reactivation of H19 expression. This 
second deletion was closer to the H I9 gene showing the silencer activity to lie within the 
first 0.8kb region of the ICR.
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There is also some evidence that CTCF is involved in maintaining differential 
methylation by blocking the methylation enzymes throughout development. Changes in 
ICR methylation have also been observed in some human cancers and may explain some 
cases of Igf2 overexpression .
In early embryogenesis genome-wide demethylation occurred with methylation 
levels hitting their lowest point at the blastocyst stage (Monk 1987). This first occurs in the 
paternal pronucelus and then spreads to housekeeping genes and regions of direct repeats. 
Imprinted genes escape this demethylation (Santos 2002). Post implantation a genome- 
wide wave of methylation was shown to occur under the control of the de novo methylation 
genes Dnmt3a and Dnmt3b (Okano 1999). When the Dnmt3a and Dnmt3b genes were 
mutated the de novo methylation activity of these genes was lost (Hseih 1999). It is thought 
that Dnmtl is responsible for maintaining methylation on the genome. It is responsible for 
copying the parental strand methylation imprint onto the daughter strand (Okano 1998). 
Knocking out Dnmtl results in a genome-wide loss of methylation and is embryonic lethal 
(Li 1992).
The gene Igf2r has areas of differential methylation also. This is a maternally 
expressed gene found on mouse chromosome 17. It has a methylated DMR (DMR2) on the 
expressed maternal allele (in intron 2) and another DMR (DMR1) on the silent paternal 
allele (in the promoter region). The maternal DMR originates in the germ cells and is 
thought to be the original imprint, which differentiates the maternal and paternal alleles 
(Birger 1999).
The gene pair Dlkl and Gtl2 behaves in a similar way to the Igf2-H19 gene pair. 
Dlkl (which is compared to Igf2 here) is paternally expressed and has a DMR which is 
paternally hypermethylated (as is Igf2 DMR1) and maternally hypomethylated. Gtl2 
(which is likened to H19 here) is maternally expressed and has a paternally 
hypermethylated DMR (Takada 2000). One major difference found between these gene 
pairs is the location of the CTCF imprinting control centre that lies in intron 1 of Gtl2 
instead of in the inter-genic region (Paulsen 2001).
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1.7.2 Acetvlation
DNA in chromosomes is packaged into chromatin, which consists of DNA and protein.
The proteins the DNA is coiled around are histones, which consist of octamers, made up of 
two units each of H2A, H2B, H3 and H4. The DNA thread is wrapped around each protein 
twice (Figure 3.)
During cell mitosis histone acetylation patterns remain and so it is a heritable 
epigenetic imprint that can influence the expression of genes (Jeppesen 1997). This 
hyperacetylation is scattered randomly throughout the genome except on the inactive 
maternally inherited X chromosome where the histones were generally hypoacetylated.
Igf2 DMR1 is rich in acetylated histones with the hypomethylated maternal DMR1 
having more acetylation than the paternal hypermethylated DMR1. This could mean that 
the maternal DMR1 may have a more open chromatin structure than the paternal DMR1. 
This allows maternal DMR1 to interact with repressors. A protein called MeCP2 that binds 
to methylated sequences of DNA also forms complexes with histone deacetylase (Bestor
1998). Inhibiting histone deacetylase with trichostatin A activates genes silenced by 
methylation (Bestor 1998). This indicates that chromatin could be deacetylated through 
methylation dependent pathways. However mice lacking in MeCP2 do not show biallelic 
expression of imprinted genes unlike Dnmtl knockout mice (Li, Beard et al. 1993).
The Igf2r gene has also been examined for histone acetylation. Higher levels were 
found on the expressed maternal allele than on the silent paternal allele. The antisense 
transcript was also examined and again where the active allele was found (paternal allele) 
higher histone acetylation was also found. Treatment of cells with Trichostatin A decreased 
methylation on both the sense and antisense transcripts (Hu 2000).
Examination of the histone acetylation of Air showed that on the expressed alleles, 
the DMR regions had histone acetylation and the repressed alleles were methylated in these 
regions. Again treatment with Trichostatin A led to derepression of the silenced alleles 
resulting in biallelic expression of Air (Hu 2000).
The DMR2 of the gene Snrpn is associated with PWS as mentioned in Section 
1.3.1. Paternal Snrpn DMR2 is unmethylated and highly acetylated compared to the 
maternal methylated DMR.
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Methylation •  Acetylation ■
Chromatin condensation Open chromatin formation with direction of
transcription shown by arrow.
Figure 3. Representation of methylation and acetylation of genome. Based on Figure 2. of Genomic 
imprinting (Reik 2001).
The cylinders represent the histone protein complexes with the black thread coiled around them representing 
DNA. Methylation is shown as grey circles and acetylation as grey squares. Transcription enzymes are 
represented by a white circle.
1.7.3 Replication timing and differences in meiotic recombination.
Fluorescence in situ hybridization (FISH) experiments carried out on interphase nuclei 
revealed a large number of nuclei in which one allele had replicated before the other. 
Analysis of the alleles of Igf2 showed differences in replication timing with the paternal 
allele replicating before the maternal allele . This asynchronous replication is established in 
the gametes and maintained in the foetus making it an imprinting mark as it also correlates 
with imprinted expression patterns.
Heterochromatin (tightly coiled chromatin) replicates at a later stage than 
euchromatin (loosely coiled chromatin, transcribed). These replication-timing differences 
may have left an epigenetic mark on the chromatin. The accessibility of enzymes to the 
DNA may have been affected by chromatin structure. High levels of histone acetylation 
found on active genes correlate with areas of euchromatin (Ouspenski 2003). Usually the 
paternal allele replicates before the maternal allele (Reik 2001).
Differences in meiotic recombination frequencies are associated with imprinted 
genes also. The presence of methylation reduces the frequency of meiotic recombination. 
An inversion on chromosome 7 in the HI 9 region was created and called the minute (Mnt) 
mutant. When paternally transmitted Igf2 is repressed and when maternally transmitted 
H I9 is silenced. However despite the disruption to the Igf2/H19 gene region which when 
maternally transmitted replicates wild type Igf2/H19 expression, asynchronous replication
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is unchanged. This implies that the methylation imprint can be altered without affecting 
replication timing differences (Cerrato 2003).
However, acetylation and replication timing alone are not sufficient to regulate 
imprinting patterns in the genome.
2.0 Aims
The general aim of this thesis was to assess the function of DMR1 and the effect this gene 
region had on the expression of Igf2.
This was done in two ways, firstly by deleting DMR1 and crossing these knockout 
mice with p53 knockout mice. The significance of Igf2 in cancer has already been 
mentioned in Section 1.3.2 and in Section 3.1 the significance ofp53 in cancer is 
explained. The objective was to ascertain if DMR1 caused p53 knockout mice to develop 
different tumours than had been observed previously (Donehower 1992), if tumours 
developed sooner or later than seen before, and if a deletion of DMR1 resulted in heavier 
or lighter mice than wild type, mice that grew faster or slower than wild type or if any 
organs were over or underdeveloped. The effects on body proportions of prolonged 
postnatal Igf2 expression have not been studied in detail. Previous studies have found that 
extended postnatal Igf2 expression resulted in a lean phenotype (Rogler 1994), (Ward
1994).
The second way that the effect DMR1 had on Igf2 expression was examined was by 
constructing transgenes consisting of elements of the Igf2/H19 gene region and including 
reporter genes so as the expression the various constructs had In vitro and In vivo could be 
analysed. The constructs were compared to each other to assess the role of each part of the 
gene region in controlling Ig/2 expression. Male and female transmission of the constructs 
were compared to ascertain if there were any expression differences due to imprinting 
effects. Expression between various organs were compared to determine where expression 
is highest and lowest within the mouse. The effects of methylation were also examined in 
transgenic mice and in transient transfections to determine if there was any correlation 
between expression levels observed and methylation patterns detected.
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Chapter 2: Materials and methods.
Transient transfections
Transient transfections were carried out on HepG2 cells, which are an endodermal liver 
cell line. The constructs that were transfected were called M, T, A, E and Me-14 (Figure 1). 
These constructs have been inserted into a Bluescript vector using restriction sites found in 
the polycloning site of the vector. M utilised BamHl and EcoRl restriction sites, T two 
EcoRl sites, A BamHl and Notl and both E and Me-14 used EcoRl and Notl sites to 
insert the construct. The transfections and assays were carried out as described below. 
Constructs E and Me-14 differ in only one aspect, namely that construct Me-14 has two 
restriction sites in its DMR (Figure 1) so that the central portion of DMR1 can be excised, 
methylated and replaced in the construct prior to cell transfection and assay of luciferase 
levels.
2.1.1.Plasmid preparation (Ward 1997)
LB-agar (per litre: 950ml of deionized H20 , lOg bacto-tryptone, 5g bacto-yeast extract, 
lOg NaCl, pH 7.0, 0.2ml NaOH, 15g Bacto-agar, autoclave for 20min at 151b/sq. in.) with 
1 pl/ml ampicillian (50mg/ml) was inoculated with scrapings from glycerol stocks stored at 
-80°C and incubated overnight at 37°C. 2ml of LB-broth (per litre: 950ml of deionized 
H20 , lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 0.2ml of NaOH, autoclave for 
20min at 151b/sq. in.) with lpl/ml ampicillian (50mg/ml) was inoculated with a single 
colony from the overnight LB-plate. This was incubated overnight at 37°C in a shaking 
incubator. 200ml of LB-broth with ampicillian (50mg/ml) was inoculated with 2ml of the 
overnight culture and incubated at 37°C overnight.
The plasmid extraction was carried out using a ‘Qiagen EndoFree™ Plasmid Maxi 
Kit’. This kit yields ultra pure, endotoxin-free plasmid DNA suitable for transfection of 
cultured mammalian cells. The DNA was eluted as detailed in the manufacturers 
handbook. Plasmid purification is based on the interaction between the negatively charged 
phosphates of the DNA backbone and the positively charged diethylaminoethanol groups 
that reside on the surface of the resin found in the Qiagen columns.
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The plasmid DNA was recovered by centrifugation at 1 l,000rpm for lOmin and 
resuspended in 200pl TE (lOmM Tris.Cl, ImM EDTA).
2.1.2: Agarose gel electrophoresis and ultra-violet light spectrophotometry. 
(Sambrook 1989)
A 1% agarose gel (0.5g/50ml) was used (0.5g agarose, 50ml TAE: 0.04M Tris-acetate, 
0.001M EDTA). 9pl of plasmid solution with lp l of loading dye (Promega, 6X) was 
loaded into each well and electrophoresed at 70Volts for 1 hr alongside a lkb marker 
(Promega).
The plasmid concentration was estimated in comparison with the lkb marker and 
confirmed using UV spectrophotometry. The plasmid was diluted to a 1/100 dilution with 
TE and the absorbance measured at 260nm. A reading of l=50pg/ml of plasmid DNA.
2.1.3: Maintenance of HepG2 cells.
HepG2 5ml (per litre: Amphotericin B 250pg/ml (GibcoBrl), 5ml Penicillin/Streptomycin 
(P/S GibcoBrl), 25ml Fetal Bovine Serum (FBS, GibcoBrl), 500ml DMEM/NUT. Mix.F12 
with Glutamax-11 (GibcoBrl)) medium was pre-warmed in a 37°C water bath.
HepG2 cells were removed from frozen nitrogen and thawed. 5ml of HepG2 
medium was slowly added to the cells. 25ml of medium was dispensed into a flask and the 
suspended cells were added to the medium. The medium was changed every 48hrs and the 
cells were passaged every four days.
2.1.4: Transfection of HepG2 cells.
Two sets of 1.5ml microfuge tubes were labelled, one set for the plasmid DNA and one set 
for the serum free medium (SFM, GibcoBRL). Into the first set of tubes 2pg of luciferase 
reporter plasmid construct and 2pg of Beta Galactosidase reporter construct was dispensed.
Into the second set of tubes, 200pl of SFM and 6pl of Fugene 6 (Boehringer) was 
dispensed. This was left at room temperature for 5min. The SFM/ Fugene 6 mixture was 
pipetted into the DNA mixture and left at room temperature for 15min. Fresh medium was 
pipetted into the HepG2 wells in the six-well plates and then lOOpl of the above mixture 
was added to each well. This was gently mixed and left for 48hr at 37°C.
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The old medium was aspirated and the HepG2 cells rinsed twice with 10ml of 
phosphate buffer solution (PBS, per litre: 8g NaCl, 1.44g NajHPO^ 0.24g KH2P 0 4, 800ml 
sterile H20 , pH 7.4, sterilise by autoclaving). lOOpl of lysis buffer (25mM Tris.H3P 0 4, 
2mM DTT, 2mMCDTA, 10% glycerol, 1% Triton X-100, pH 7.8) was dispensed and left 
at room temperature for 20min and then transferred into 1.5ml microfuge tubes.
2.1.5 Assay for luciferase.
Solutions of luciferase were prepared from a stock solution at 2ng/lpl to make a standard 
curve by diluting to 10'1, 102 up to 10'5 ng/pl. 5pl of each cell lysate was loaded in 
duplicate into 96 well microtitre plate and then the standard curve dilutions were loaded, 
also in duplicate. Light emission was assayed using a luminometer (EG&G Berthold 
Microplate Luminometer LB 96V) which dispensed 25pl of luciferase reaction mixture 
(Promega) and after a delay of lOsec counted emitted light (photons). The resulting figures 
(relative light units, rlu) were entered into an Excel worksheet, which calculated the log of 
the rlus and the log of the standard curve rlus. Using the standard curve the total ng of 
luciferase in the sample was calculated taking into account the dilution factor used in the 
assay sample well.
2.1.6 Assay for beta-galactosidase.
Beta-galactosidase was co-transfected along with the luciferase construct to compare 
transfection efficiency. This is a colorimetric reaction where 0-nitrophenyl-p-D- 
galactopyranoside converts the colourless substrate into a bright yellow liquid as an 
indicator of beta-gal transfection levels. 20pl of each cell lysate was loaded into another 96 
well plate in duplicate and the last two wells were loaded with lysis buffer alone and 
blanks. 140pl of buffer A (0.06M Naj HP04, pH 7.0, 0.4 M NaH2P 0 4, 0.01M KCL,
0.001M M gS04, 0.05M p-mercapto-ethanol) 25pi of O-nitrophenyl-P-D-galactopyranoside 
(ONPG, 4mg/ml solution of ONPG dissolved in 0.1 M sodium phosphate) was added to 
each well. This was incubated at 37°C for 30min to 2hr and absorbance was measured at 
405nm in a colorimeter (Rosys Anthos 2001). The absorbancies were entered into the same 
Excel worksheet as the luciferase results, but in this case without a standard curve.
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2.1.7 Assay for protein
Protein levels were assayed as an indication of relative cell number transfected with the 
plasmid. This is a colorimetric reaction with a blue colour indicating protein levels in the 
cell lysis sample. A standard curve was made using BioRad protein assay standard II 
(BioRad). This was diluted to 1 mg/ml. Then the following concentrations of the assay 
standard were made by dilution using sterile H20  or 1/10 lysis buffer: 0.1, 0.2, 0.4, 0.6, 0.8 
and 1.0 using sterile H20  or 1/10 lysis buffer (as before). Cell lysates were diluted to a 1/10 
or 1/20 dilution with sterile H20. lOpl of the diluted cell lysates were loaded in duplicate 
into a 96 well plate together with the standard curve dilutions. 200pl of BioRad assay 
solutions (BioRad) was added to each well and left at room temperature for 30min. The 
absorbancies were entered into the same Excel worksheet as mentioned above along with 
the absorbancies of the standard curve. The worksheet then used the curve to calculate the 
total amount of protein present in the cell lysis samples again taking into account the 
dilution factors used.
2.1.8 Data analysis
Three sets of figures were generated in the Excel worksheet, the total amount of luciferase 
(ng) in the cell lysis samples, the beta-gal absorbancies and the total amount of soluble 
protein (mg) in the samples. The amount of luciferase was divided by the amount of 
protein which was then divided by the beta-gal absorbancies to give the total ng of 
luciferase present in the sample corrected for cell number (protein assay) and transfection 
efficiency (beta-gal assay). All analysis was carried out using the Prism programme.
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2.1.9: Patch methylation transfections.
2.1.9.1: Plasmid preparation, agarose gel electrophoresis and UV spectrophotometerv
Construct Me-14 was prepared as described in Section 1.1. of Materials and methods and 
the plasmid concentration was estimated as described in Section 1.2 of Materials and 
methods.
2.1.9.2: Patch methylation of construct.
The DNA was split into two tubes and two methylation reactions were set up. One tube 
was methylated and the other was mock-methylated as a control for the processing steps. 
The enzyme used to methylate is Sssl, which methylates all cytosine’s in CpG 
dinucleotides (NEB). 10 units of methylase were used for every l-5pg DNA. Into each 
tube 50pl of DNA was added, lOpl of 10X NEB buffer 2, lOpl Sssl (or water), 2pl S- 
adenosyl-methionine (SAM), 28pl sterile H20. These were incubated overnight at 37°C 
with the SAM renewed after 3-4hr in both tubes.
Then lOOng of the DNA was digested with Hpall for l-2hr at 37°C. Gel analysis 
showed that the mock-methylated sample had digested into smaller fragments and the 
methylated DNA was intact. The DNA was then purified using a Qiagen nucleotide 
purification kit and eluted in 50pl. The DNA yield was estimated on a gel.
The vector and insert were ligated together at a ratio of 3-5:1 insert: vector with 2pl 
of ligase used for every 5pg of total DNA. The ligation reactions were incubated overnight 
at 4°C. The reactions were then purified using a Qiagen nucleotide purification kit and 
eluted in 50pl as per the manufacturers instructions.
2.2.1 Transgenics
The constructs used in the transgenics experiments all contain DMR1, the P3 promoter and 
either the luciferase reporter gene or the beta-galactosidase (lacZ) reporter gene. They also 
contained either or both of the H19 enhancer and the centrally conserved domain (CCD) 
(Figure 1) FI mice (C57BL6/CBA) were used for superovulation as they have a high egg
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production rate (between 40 to 60 per mouse). MF1 mice were used as pseudopregnants 
because they are an outbred line and make good foster mothers.
The mice have a 12hr light/dark diumal cycle with light occurring between 8am 
and 8pm. They were assumed to have mated at midnight in the dark cycle of the night 
before a copulation plug was detected. From this, it was known when embryos had reached 
embryonic day 14.5 (E14.5) and day 1 post birth (dayl).
2.2.1.2 Creating new transgenic lines. (Hogan 1994)
FI females (as described above) were injected with Pregnant Mares Serum (PMS, mimics 
follicle-stimulating hormone) 46-48hr prior to ovulation and Human Chorionic 
Gonadotropin (hCG, mimics luteinizing hormone) 10-13hr prior to ovulation as described 
in Manipulating the Mouse Embryo (Hogan 1994) to cause superovulation. MF1 females 
were mated with vasectomised males to generate pseudopregnant mice, which were the 
recipients of the injected embryos.
The superovulated FI mice were mated when in oestrus with stud males and the 
embryos were harvested and suspended in M2 medium (5ml stock A{947mM NaCl, 
4.78mM KCL, 11.9mM KH2P 0 4, 11.9mM MgS04, 232mM sodium lactate, 55.6mM 
glucose, 0.03g penicillin, 0.025g streptomycin}, 0.8ml stock B (250mM NaHC03, 0.01% 
phenol red}, 0.5ml stock C (33mM Na pyruvate}, 0.5ml stock D, (17.1mM CaCl22H20}, 
4.2ml stock E, (250mM HEPES} and 200mg bovine albumin (sigma 96-99%), 39ml 
sterile H20 , filter sterilised).
The constructs (prepared as in Section 2.1.2 of materials and methods) were injected into 
the embryos while they were suspended in KSOM medium (1ml stock A’ {950mM NaCl, 
25mM KCL, 3.5mM KH2P 0 4, 2.0mM M gS04, lOOmM sodium lactate, 2.0mM glucose, 
0.03g penicillin, 0.025g streptomycin}, 1ml stock B {as before}, 0.1ml stock C’ {20mM 
Na pyruvate}, 0.1ml stock D (as before}, lp l stock F {100mM Na2EDTA2H20}, 50pl 
stock G, {200mM glutamine}, lOmg Bovine albumin (Sigma 96-99%) and 7.8ml sterile 
H20 , filter sterilised) using Clark GC100+0 borosilicate glass capillaries (1mm OD x 
0.58mm ID, standard wall, with filament) pulled into a long, sharp, tapered needle using a 
Sutter P-97 Flaming/brown Micropipette Puller using the parameters set in programme 33 
(Heat = 275, Pull=170, Velocity = 175, Time = 150). The embryos were held in position 
using Clark GC100+0 borosilicate glass capillaries (1mm OD x 0.58mm ID, standard wall,
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without filament) were polished using Beaudoin Microforge No. 620. A Nikon Eclipse 
inverted microscope was used to carry out the injections with Nikon Narishige motorised 
joysticks used to manipulate the embryos.
These injected embryos were transferred into the oviducts of the pseudopregnant 
mice and the litter was tested for transgenic pups when bom by PCR (Section 2.1.3) and 
Southern blotting (Section 2.1.3).
2.2.2 Preparation of DNA for transgenesis microiniection.
Insert DNA was cut out from the plasmid (at least 50pg) using appropriate restriction 
enzymes. This was run on an agarose gel using a preparative comb at 60Volts to 
completely separate vector from insert. Insert was cut out of the gel and purified using a 
QIAquick Gel Extraction Kit (Qiagen) as per the manufactures handbook.
A Sartorius micro collodion bag (cat no. SM13202K) was placed in a beaker of 
sterile H20  for one hour to rinse away the ethanol it was stored in. The volume of the 
eluted DNA was recorded and transferred into the bag, which was placed in a beaker half 
full of dialysis buffer (5-10mM Tris pH 7.4, 0.1-0.25mM EDTA in sterile H20 , filter 
sterilised). This was left at 4°C overnight. The dialysis buffer was changed morning and 
night for the next 48hr.
The dialysed DNA was removed from the bag, its volume recorded and placed in a 
Costar Spin-X Filter. This was centrifuged at full speed for one min. The concentration of 
this was calculated using the equation: spec reading x 100 x 50 = Xpg/ml at 260nm and a 
concentration of 0.5-lng/pl was used for injection. This was checked on a 1% agarose gel 
also.
2.2.3 Genotvping of litters.
Ear and tail biopsy samples were obtained when the pups reached three weeks. The ear 
samples were used for PCR and the tails were used for Southern blotting.
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Polymerase Chain Reaction fPCR).
600pl of 50mM NaOH was added to each ear sample and boiled for lOmin. This was left 
to cool and then vortexed for 30sec. 50pl of Tris (pH 8.0, 1M) was added and the samples 
were vortexed again.
Into labelled PCR tubes 23 pi of Reddy Mix PCR Master Mix (Abgene, IX conc.) 
was added, lp l of Primer Mix (from 15pM stocks, lOOpl of each primer added) and lp l of 
the ear prep mixture. A control was made using just primer mix and Reddy Mix. The PCR 
was carried out in a Techne Touchgene (Jencon) PCR machine under the conditions set out 
in programme Geno 60 (30 cycles, lmin 94°C, lmin 60°C, lmin 72°C).
Southern blotting.
About 24pl (or lOpg) of each sample was digested with a suitable restriction enzyme and 
electrophoresed on a 1% agarose gel, transferred onto Hybond membrane (Amersham) and 
hybridised with DMR1 probe using the Church and Gilbert method. A DMR1 fragment 
used as a probe was cut from a construct p l7al4  using BamHl. This gave a 2.5kb band 
which was then purified using QIAquick Gel extraction kit (Qiagen) following the 
manufacturers instructions. The purified DMR1 fragment was then labelled using 32P- 
dCTP (Amersham) (see below).
The gel with the digested DNA samples was depurinated for 15min using 
depurinating solution (0.2M HCL) and then rinsed with milliRO H20. It was then 
immersed in denaturing solution (0.5M NaOH, 1M NaCl) for 15 min. This was then 
washed twice for 20min in neutralising solution (1.5M NaCl, 50mM Tris-HCL, pH7.2, 
ImM EDTA). A blotting tank was set up with 20X SSC (3M NaCl, 0.3M Sodium Citrate, 
pH 7.0) and the gel was left to blot overnight.
2X SSC was used to wash the membrane, which was then crosslinked on the 
transilluminator for 2min. Church buffer (per litre: 15ml PB, 60pl 0.5M EDTA, 2.1g SDS, 
0.3g Bovine Serum Albumin, 14ml MilliQ water) was warmed to 65°C and 400pl of 
salmon sperm DNA (lOOmg.ml denatured and sheared) was boiled for 5min. The 
membrane, the warmed Church buffer and the salmon sperm DNA were added to the 
hybridisation bottle and left to hybridise at 65°C for 2hr in a Hybaid hybridisation oven in 
which samples can be mixed by constant rotation.
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To label the probe 20ng of probe DNA was made up to 12.5pl in MQ H20  and was 
boiled for 5min and then chilled on ice for 5min. 4pl of ‘HiPrime’ and 2.5pl o f[32 P] dCTP 
to label to a high specific activity was added. This mixture was left at 37°C for at least an 
hour. Meanwhile a spin column was prepared by plugging the end of a 1ml syringe with 
glass wool, this was filled with Sephadex G50 and equilibrated by spinning for 4min at 
1200rpm. The labelling reaction was made up to lOOpl with TE. The labelled probe was 
added to the spin column and centrifuged at 1200rpm for 4.5min, having placed a 1.5ml- 
microfuge tube in the tube to collect the flow-through. lOOpl of TE was added and it was 
recentrifuged. 400pl of salmon sperm DNA was added, the mixture reboiled for 5min and 
chilled on ice for 5min, then added to the prehybridising solution and left rotating at 65°C 
overnight.
Wash solution (40mM PB, lOgSDS, 2ml 0.5M EDTA) was warmed to 65°C, the 
hybridising solution was poured off and the tube filled with wash solution for 15min. This 
was repeated with another 15min wash, followed by a final lhr wash. The membrane was 
then rinsed in 480ml MQ H20  with 20ml PB to remove SDS. Saran wrap was used to wrap 
the membrane and it was put in a cartridge with film (Biomax-MR, Kodak, X-ray film for 
autoradiography) and left at -80°C to develop. When it was ready, it was developed using 
an X-Ograph Compact X2 developer.
2,2.4 Luciferase assays in transgenic tissues
The tails of the Dayl pups and the heads of the El 4.5 embryos (heads were homogenised 
using an Ultra-turrax T8 IKA Labortechnik for approx. 10 sec) were used in a luciferase 
assay to test which individuals were transgenic. The heads and tails were vortexed in lysis 
buffer (25mM Tris-phosphate, pH 7.8, 2mM DTT, 2mM 1 2-diaminocyclohexane-N,N,N’, 
N ’- tetraacetic acid, 10% glycerol, 1% Triton X-100) and lOpl aliquots were assayed for 
luciferase in a luminometer (EG&G Berthold microplate Luminometer LB 96V) which 
dispensed 25pl of luciferase assay substrate (Promega) and after a delay of lOsec counted 
light emissions (as in Section 1.1.5 of Materials and methods).
A reading of >200rlu was considered positive for the luciferase transgene as a 
blank control typically gives a reading of 85-120rlu. Any individuals with this result were 
further assayed. The brain, tongue, liver, kidney and muscle of the Dayl pups and the 
body, placenta and yolk sac of the E l4.5 embryos were assayed as described above.
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2.2.5 Protein assays in transgenic tissues.
A protein assay was carried out on the E l4.5 heads and on the brain, tongue, liver, kidney 
and muscle of the Dayl transgene positive pups and the body, placenta and yolk sac of the 
E14.5 transgene positive embryos. A standard curve was made as described before (Section 
1.1.7 of Materials and methods). The samples were diluted with water as follows: Brain 
1/50, tongue 1/20, liver 1/50, kidney 1/20 and muscle 1/10. Head 1/20, body 1/50, placenta 
1/50 and yolk sac 1/20. lOpl of these diluted samples was dispensed in duplicate into a 96 
well plate and the absorbencies measured at 405nm in a colorimeter (Rosys Anthos 2002).
2.2.6 LacZ staining of tissues.
Tissue stain base solution (0.1M P 04 buffer{ 40.5:9.5 of N a^N aH ;,, pH 7.4), 2nM 
MgCl2, 0.015 sodium deoxycholate, 0.02% Nonidet P-40, 5mM K3Fe(CN)6, 5mM 
K4Fe(CN)6) was warmed to 37°C and kept in the dark. A 1/40 dilution was made with the 
X-Gal stock solution (40mg/ml X-Gal dissolved in DMSO) using the warmed tissue base- 
stain solution and kept in the dark at 37°C until needed.
The tissues were fixed in Tissue fixative (0.1M P 04 Buffer, pH7.4, 4% 
paraformaldehyde, 2mM MgS04, 5mM EGTA) for 45min to 1.5hr on wet ice. Then they 
were rinsed in Tissue rinse solution A (0.1M P 0 4 buffer, 2mM MgCl2, 5mM EGTA) and 
washed in Tissue rinse solution A for 30min at room temperature. The tissues were rinsed 
in Tissue rinse solution B (0.1M P 04 buffer, 2mM MgCl2, 0.01% sodium deoxycholate, 
0.02% Nonidet P-40) and washed in Tissue rinse solution B for 5min at room temperature. 
The tissues were drained and the complete P-Gal Tissue stain solution was added and left 
at 37°C in the dark for >lhr.
2.2.7 DNA extraction from mouse tissues.
Approx. 500mg of each organ was placed in a labelled tube and 525pl of tail buffer (50mM 
Tris, pH 8.0, lOOmM EDTA, lOOmM NaCl, 1% SDS , 265ml sterile H20 ) and 35pl 
lOmg/ml protinase K was added. This was left at 55°C overnight.
2pl 0.2mg/ml RNase A was added and the sample incubated at 37°C for lhr. 200pl 
of 5M NaCl and 700pl of chloroform:isoamylalcohol (24:1) was added and left mixing on
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a rotator for 2hr. These were centrifuged at 10,000rpm for 1 Omin and the upper aqueous 
layer was dispensed into a fresh tube. This was centrifuged at 15,000rpm for 15min and the 
supernatant was removed. The remaining pellet was then washed for lhr at 4°C with 300pl 
of 70% ethanol. The ethanol was thoroughly removed and the pellet resuspended in 200pl 
of TE (lOmM Tris, pH 8.0, ImM EDTA and sterile H20 ) overnight at 4°C.
2.2.8 Southern blotting of mouse tissues.
The tissues were digested with restriction enzymes and blotted as described in Section
2.2.1.3 of materials and methods.
2.3. AU2/ P53 Mouse Experiments.
Mice aged >9 months were culled and blood samples and selected organs removed. The 
organs preserved were the brain, a liver section, spleen, pancreas, gonadal fat pads, renal 
fat pads and the left hind leg.
The mice were culled and a syringe was used to extract aortic blood from the aorta 
of the heart (~lml). This was then left at 37°C for lhr, and then centrifuged at full speed for 
5min, the serum removed and stored at -80°C. The samples were then sent for analysis to 
Dr. Domenico Accili ay Columbia University.
The organs were preserved in PFA (4% paraformaldehyde in PBS, 5 PBS tablets in 
500ml H20 , 20g paraformaldehyde left on heated stirrer until it reached 60°C. Added drops 
of NaOH until PFA dissolved pH 7) overnight at 4°C, and then embedded in wax for 
histological analysis. The organs were stained with eosin and heamotoxilin (E+H)and the 
livers were also stained with PAS to detect glycogen.
Any tumours removed were also preserved as above and stained with H+ E also and 
sent for pathological analysis to Sweden.
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Figure 1: Constructs used in transgenic mice and transient transfections.
Letters denote construct name. The regions represented are: Differentially methylated region 1 (DMR1 red 
boxes), the Ig fl P3 promoter (orange boxes), luciferase reporter gene (yellow arrow), lacZ reporter gene 
(green arrow), HI9 enhancers (blue circles) and the centrally conserved domain (CCD, purple boxes. Black 
vertical arrows denote the restriction sites Aatll and Ndel.
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Chapter Three: Analysis of growth and tumour formation in mice doubly mutated
for p53 and Igf2AU2 knockout alleles
3.1 Introduction:
p53 knockout mice (Donehower 1992)
Thep53 gene restrains mammalian cells from entering the S phase halting it at Gl. 
Mammals with a mutated from of the gene have a predisposition to various cancers. P53 
signals to a cell when it has been damaged. The cell death associated protein kinase DAPK 
sends stress signals to p l4 ARF', which controls a protein called MDM2. MDM2 causes the
A R  F* •destruction ofp53 in normal cells, but in cancer cells there is a loss of p l4  leading to
overexpression of MDM2 and inactivation ofp53 (Jones 2001). Mutations in p53 have 
been observed in more than 50% of all spontaneous human cancers. Li-Fraumeni 
syndrome is also associated with p53. Usually cells with one normal copy of the gene do 
not form tumours and cells in which both copies have been altered frequently go on to 
develop into tumours.
The p53 gene is dispensible for normal development and p53 protein levels are 
normally very low in wild-type cells. Human deletions ofp53 are associated with tumours 
of the liver, bladder, brain, lung, breast, colon, oesophagus and ovary (note the prevalence 
in female reproductive organs) (Donehower 1992). However, mice in which both alleles of 
p53 have been inactivated by gene targeting develop tumours at a very early age, usually 
before 6 months. The tumour spectrum observed in p53 null mice included lymphomas, 
mostly in the thymus and some in the heart, lung, spleen, liver, kidney and brain, and 
sarcomas, mostly haemangio-sarcomas. When p53 wild type, heterozygous and null mice 
were exposed to 1,2-dimethylhydrazine (DMH) over a period of 16 weeks it was found 
that the null mice went on to develop carcinomas of the colon but the heterozygotes and 
wild types did not. When the experiment was carried out for a longer period of time 
however the significant difference in the occurrence of tumours disappeared. This implies 
that p53 null mice may have accelerated tendencies towards tumour formation initially, but 
this effect is lost over time (Sakai 2003). Investigations carried out on T cells inp53 null 
mice revealed that the cells were predisposed to become polyploid more frequently than in 
wild type mice. This is due to a failure at the mitotic checkpoint during cell division. P53 
null mice spontaneously develop tumours of the spleen and thymus as do p53 heterozygous 
mice but at a lower frequency. (Baek 2003).
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Exons 2 to six of the gene were deleted in the mice used for this experiment (Clarke 
1993). Unlike previous p53 knockout mice these mice developed tumours in the 
gastrointestinal system as well as in the thymus, spleen, heart, lungs, liver, kidneys and 
brain. These mice were shown to have a p53 dependent pathway to apoptosis in 
thymocytes.
7g/2 AU2 mutant mice (Constancia 2000)
A 5kb region at the 5’ end of Ig/2, including differentially methylated region one (DMR1) 
and the adjacent repeat were deleted in mice and the effect of the deletion was examined 
following both maternal and paternal transmission. It was thought that DMR1 contained a 
silencer that was functional in the unmethylated maternal allele and that deletion of this 
silencer would instigate expression of Igf2 from the maternal allele. Following maternal 
transmission of the Igf2AU2 allele tissues of predominantly mesodermal origin were found 
to have biallelic expression of Ig/2 (heart, kidney and lung), and endodermal (liver) and 
placental tissues retained paternal expression of the gene. Maternal transmission of the 
deletion also resulted in continued postnatal expression of Ig/2 from the maternal allele. 
Expression from the paternal allele was similarity prolonged following paternal 
transmission by postnatal day 10. Paternal transmission otherwise resulted in a 
transcription rate the same as in wild type mice, but with intrauterine growth retardation 
associated with lack of expression of placenta specific transcripts. These mice were at birth 
71% the weight of normal mice but catch up to their wild-type littermates after weaning. 
The deletion of DMR1 and the adjacent repeat had no effect on H I9 expression.
3.2 Aims:
As part of this study 7g/2AU2 and p53 knock out mice were crossed with each other, these 
mice were weighed once a week and if a weight loss of more than 10% of the total body 
weight of the mouse was detected the mouse was culled and dissected with the aim of 
detecting tumours. Also any tumours detected independently of a 10% weight loss were 
similarly culled and processed for histology. This was done to determine if the tumour 
spectrum changed when p53 knockout mice also had a deletion in DMR1 and also to see if 
any tumours developed sooner or later than expected. The postnatal effects of prolonged 
Ig/2 expression associated with the 7g/2DMRl mutant have not been studied in detail. Here 
we have looked for changes in body proportions and have included analysis of white 
adipose tissue since previously, prolonged expression of IGF2 transgene has resulted in a
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lean phenotype (Rogler 1994; Ward 1994). Any remaining mice were dissected and their 
organs were weighed and their blood analysed for circulating glucose levels to determine if 
any organs were disproportionally larger or smaller and whether there was any correlation 
between glucose levels and body fat.
3.3 Results:
In total 96 mice were weighed over a period of 12 months.
82 of these mice were culled and 14 died of unknown causes .Of the 82 that were culled 10 
were because of a greater than 10% weight loss , 9 because of an obvious tumour, 44 were 
culled to analyse their brain, liver, kidney and gonadal fat pad weights and 19 were culled 
to analyse their tissues at the end of the experiment.
3.3.1 Mice that died of unknown causes
The 14 mice in this group that died of unknown causes were spread over six genotypes as 
shown in Table 1. This is also represented graphically in Figure l.Most of these were 
p53het (8 mice), 5 were p53nulls and only one was a p53 wild type. 4 had a maternally 
inherited deletion of DMR1, 4 had a paternal deletion of DMR1 and 6 were wild type for 
DMR1. No single genotype was significantly represented in this group of mice.
Genotype Number of mice in sample No. of mice that died of 
unknown causes.
AU2hetM/p53het 29 3









Table 1. Summary of mice that died of unknown causes.
AU2 refers to the DMR1 status o f the mice, hetM is a maternal deletion o f DMR1, hetP is a paternal deletion 
o f DMR1 and wt is wild type DMR1. p53het mice are heterozygous for the p53gene, p53nulls are knockout 
mice and p53wt are mice that are wild type for the p53 gene.
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Figure 1.
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Genotypes of unknown cause of death mice
Figure 1. Genotypes of mice that died of unknown causes.
U2 stands for deletion o f DMR1, M or P stands for a maternal or paternal deletion of DMRl.p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice.
The ages at which these mice that died of unknown causes ranges from 3 months to 19 
months with the majority of mice dying after 12 months of age (Figure 2). This is not 
significantly different from what was observed with the p53 knock out mice and so the loss 
of DMR1 did not cause this group to live for a longer or shorter period. There is no 
statistically significant difference between p53het mice and p53 null mice (p= 0.153) and 
there were insufficient samples to compare p53het with p53null. There were also no 
differences in the age at death between the maternally deleted DMR1 and DMR1 wild type 
(p= 0.114). Paternally deleted DMR1 was also not any different to wild type DMR1 (p= 






U2hetM/p53het U2hetM/p53wt U2wt/p53het U2wt/p53null U2hetP/p53het U2hetP/p53null
Genotypes of mice that died of unknown causes
Figure 2. Genotypes of mice that died of unknown causes and the ages at which they died.
U2 stands for deletion of DMR1, M or P stands for a maternal or paternal deletion o f DMRl.p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice.
The 82 remaining mice fell into four different categories. Firstly there were those mice that 
lost greater than 10% of their total body weight in one week, secondly there were those 
mice that developed obvious tumours, thirdly were the mice that were culled in order to 
weigh their organs and analyse their blood and finally the remaining mice were culled at 
the end of the experiment and their tissues examined (Figure 3.).
Figure 3.
50-.
>10% Tumour Analysis End 
Reason for Culling
Figure 2.Reason for culling of mice that did not die from unknown causes.
This bar chart represents the reasons the 82 mice were culled.
10 were culled due to a greater than 10% loss in total body weight (>10%), 9 were culled due to the 
appearance of an obvious tumour (tumour), 44 were culled to analyse their aortic blood and organ weights 
(analysis) and 19 were culled and their tissues examined at the end of the experiment (end).
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3.3.2 M ice that lost more than 10% of their total body weight in one week
Weight loss of 10% or more was used as an indication of possible tumour formation before 
a visible tumour could be detected. 10 mice out of the 96 lost >10% of their total body 
weight in one week and 8 of these 10 had an organ abnormality (Figure 4.). 2 mice had no 
visible cause for the weight loss. The majority of these mice had developed tumours of the 
thymus and one had an enlarged spleen. Thymus tumours are not unusual in p53 knock out 
mice and an enlarged spleen can be an indication of an infection rather than any genetic 







Results of analysis of >10% Wt. loss 
mice
Figure 4. Cause of death of mice that lost >10% in one week.
This bar chart represents 10 of the 82 culled mice. These 10 mice had a greater than 10% weight loss from 
one week to the next. When dissected 7 were found to have thymus tumours (Thymus), 2 had lost weight due 
to unknown causes (Unknown) and one had an enlarged spleen (Spleen).
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The majority genotype observed in the mice that lost >10% total body weight in one week 
was the AU2wt/p53null genotype (Figure 5.). It accounted for half of the mice in this 
group. When added to the 2 mice that were also null forp53 but had a paternal deletion of 
DMR1 it is now 7 out of the 10 mice that were in this group.
Figure 5.
U2hetM /p53het U2wt/p53null U2hetP/p53het U2hetP/p53wt U2hetP/p53null
Genotypes of mice with >10% weight loss
Figure 5. Genotypes of mice that lost more than 10% of their total body weight in one week.
U2 stands for deletion of DMR1, M or P stands for a maternal or paternal deletion of DMRl.p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice.
The /?J3null mice were the mice that had tumours of the thymus most frequently which 
correlates with previous findings of p53 knockout mice developing tumours of the thymus 
(Figure 6.). The mice that had an unknown reason for the weight loss were p53 wild types 
and had either a maternal or paternal deletion of DMR1. It is possible that their weight loss 
was not due to tumour formation but some other pathological factor. The mouse with the 
enlarged spleen was also a p53 null but wild type for DMR1 and may have had an 
infection, which led to its weight loss.
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Figure 6. Genotypes of mice that lost more than 10% of their total body weight in one week and the 
ages at which they were culled.
U2 stands for deletion of DMR1, M or P stands for a maternal or paternal deletion of DMRl.p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice. Thymus represents thymus tumours, spleen represents and enlarged spleen and unknown 
represents no known cause for the weight loss in these mice.
Thymus tumour (1), thymus tumour (5) and enlarged spleen (19) were sent to a pathologist 
for analysis. The diagnosis given for both of the thymus tumours were malignant 




Spleen (19) Thymus tumour (5)
Figure 7. Tissue sections from mice with >10% weight loss.
The sections were stained with H+E and are shown here at x20 magnification. The numbers in brackets refer 
to the numbers given to tumours and altered organs for identification.(see table 2 for details)
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3.3.3 Tumour development
Of the 9 mice that developed abnormalities without any detectable weight loss the 
majority had abnormal lymph nodes (3 out of 9 mice). Most of the abnormalities were 
found in the mice with a maternal deletion of DMR1 and were heterozygous for p53 
(Figure 8.). None of the mice that developed abnormalities were wild type for p53 or 
DMR1. The tumour spectrum in this group is more varied than in previous groups but is 
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Genotypes of tumour mice
Figure 8. Genotypes and tumours of mice that developed tumours without any weight loss.
U2 stands for deletion of DMR1, M or P stands for a maternal or paternal deletion of DMRl.p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice.l subcutaneous tumour (Sub), 2 spinal tumours (Spinal), 1 vaginal (Vag),
3 lymph node tumours (Lymph), 1 facial tumour (Facial) and 1 mouse with a leg abnormality (leg).
There is no statistical difference between the three genotypes regarding the ages of the 
mice at death (Figure 9.). However when compared to the group of mice that showed 
weight loss before physical abnormalities there is a significant difference between the two 
groups (p= 0.0039). The mice that showed >10% weight loss died sooner than the mice 
that developed abnormalities. Also the >10%weight loss group mostly developed thymus 
tumours whereas the second group mostly developed lymphomas. It appears that thymus 
tumours can be associated with weight loss and lymphomas are not. The weight loss could 
be due to changes in metabolism due to alterations within the thymus as the thymus not
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only controls immune mechanisms but has been associated with eczema, lupus, some 





























Genotypes of mice with tumours
Figure 9. Genotypes and ages at death of mice that developed tumours.
U2 stands for deletion of DMR1, M or P stands for a maternal or paternal deletion of DMR1 ,p53wt are mice 
that are wild type for the p53 gene, p53het are mice that were heterozygous for the p53 gene and p53null are 
p53 knockout mice. Spinal stands for a tumour of the spinal column, vaginal represents a tumour of the 
vagina, unknown is for an unknown cause for the mouse to be unwell, subcut. represents a subcutaneous 
tumour of the skin, facial represents a tumour visible on the face and lymph represents a tumour found in a 
lymph node.
When a selection of the spontaneous tumours were sent for pathological analysis the 
following results were given (Figure 10):
The subcutaneous tumour (2) was diagnosed as a mammary adenocarcinoma and the 
lymph tumour (9) was diagnosed as a malignant lymphoma, lymph tumour (7) was 




Figure 10. Sections of tumours that arose spontaneously.
The sections are of H+E stained sections of spontaneous tumours at x20 magnification. The numbers in 
brackets were the numbers assigned to the tumours for identification purposes, (see Table 2 for details)
3.3.4 End of experiment analysis.
At the end of the experiment there were some mice from the sample group 
remaining, which had not lost any weight, did not develop spontaneous tumours and were 
not culled for blood and organ analysis. These mice were then culled and dissected to 
determine if there were any further abnormalities that could be found which were not 
detected previously. Paternal deletion of AU2 essentially has no effect and phenotypically 
is the same as wild type, so six of the above mice (3 wild type, 3 paternally deleted) are 
phenotypically the same. The one maternal deletion is associated with the p53 wild type, 
with an unknown cause of weight loss and may or may not be the reason for the decrease 
in body mass. All of the abnormalities were found in mesodermal tissue (apart from the 
liver tumour which is endodermal), which corresponds with the biallelic expression of Igfl 
in the mesoderm seen by Constancia (Constancia M. 2002). P53 het mice usually do not 
develop tumours until they are around 9 months old, however these mice showed no 
obvious abnormalities even at 20 months, more than twice the expected age. Also the mice, 





The diagnosis given when the tumours were analysed by a pathologist were as follows: 
Seminal vesicles (11) were described as having some areas consisting of spindle cell 
sarcoma, composed of fibroblastic cells with a possible diagnosis being a malignant 
fibrous histiocytoma. Ovarian tumour (12) was described as having two possible lesions, a 
large ovarian follicular cyst and a histicytic sarcoma. Ovarian tumour (13) was diagnosed 
as a hemangioma with thrombus formation. Facial tumour (11) was diagnosed as a 
hyperkeratinized papilloma.
i  v..,- -
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Seminal vesicles (11) Seminal vesicles (11)
Ovarian tumour (12) Ovarian tumour (13)
Facial tumour (11) Uterine tumour (16)
Figure 11. Sections of tumours founding mice at the end of the experiment.
The sections are of H+E stained slides at X20 magnification. The numbers in brackets represent the numbers 
assigned to the tumours for identification purposes, (see Table 2 for details)
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3.3.5 Genotypes of tumours.
When the mice were dissected a selection of tumours were genotyped for p53 status.
(Table 2.). Ovarian tumour (12) and uterine tumour (16) both appear to have gained an 
allele, or rather, there has been a duplication event resulting in a potential UPD for p53. 
Ovarian tumour (13) has lost an allele in its development and it is notable that all of these 
changes in genotyping status occurred in the female reproductive system. Some of the 
tumours were genotyped for p53 independently of their host mouse by Tracey Crew and it 
was found as shown above that the tumour appears to have lost an allele ofp53. This is not 
unusual in tumour development and fits with Knudson’s and Strongs two hit model of 
carcinogensis. This states that both alleles of a gene must be lost in order for cancer to 
develop. A mouse that is heterozygous for p53 already has a predisposition to tumour 
formation and only requires one more mutation to develop cancer. Also this mouse 
developed cancer relatively early at 6 months which again fits with this model as mice that 
had two intact copies of the p53 gene would take longer to develop the double allele loss
required for tumour formation and so it would have occurred later in development.
Organ Genotype of mouse P53 status of tumour
End of experiment tumours
Seminal vesicle tumour (11) AU2hetM/p53het (+/-) P53het (+/-)
Seminal vesicle tumour (10) AU2hetM/p53wt (+/+) P53wt (+/+)
Ovarian tumour (12) AU2hetM/p53het (+/-) P53wt (+/+)
Ovarian tumour (13) AU2hetM/p53wt (+/+) P53het (+/-)
Liver tumour (14) AU2hetM/p53het (+/-) P53het (+/-)
Uterine tumour (16) AU2hetM/p 5 3 het (+/-) P53wt (+/+)
Spontaneous tumours
Subcutaneous tumour (2) AU2hetP/p53het (+/-) P53het (+/-)
Spinal tumour (4) AU2hetP/p53het (+/-) P53het (+/-)
Facial tumour (7) AU2hetM/p53het (+/-) P53het (+/-)
Lymph tumour (9) AU2hetM/p53het (+/-) P53het (+/-)
Spinal tumour (3) AU2hetM/p53het Not done
Facial tumour (8) AU 2hetM/p5 3 het Not done
Weight loss tumours
Thymus tumour (1) AU2hetP/p53het (+/-) P53 null (-/-)
Thymus tumour (5) AU2hetP/p53null Not done
Thymus tumour (6) AU2hetP/p53null Not done
Thymus tumour (15) AU2wt/p53null Not done
Enlarged spleen (19) AU2wt/p53null Not done
Table 2. Genotypes of mice and of tumours.
AU2het refers to the DMR1 status o f the mice with either a maternal (M) or paternal (P) deletion o f DMR1. 
The p53 status o f the mice and tumours is represented with het short for heterozygous, wt for wild type and 
null for full knock out.
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3.3.6 Mice culled for analysis
There were 4 genotypes in this group of culled mice. They were:
AU2 hetF/P53null, AU2 hetF/P53het, AU2WT/P53null and AU2WT/P53. All were culled 
between 9 and 10 months of age. These mice were culled in order to weigh their organs 
and take blood samples to measure glucose levels. A tumour which was found when the 




Spleen (1) Spleen (10)
Figure 12. Sections of organs from mice culled at 9-10 months for organ weight analysis.
The sections were stained with H+E and shown here at X20 magnification. The numbers in brackets 
represent numbers assigned to the tumour or organs for identification purposes (see Table 2 for details)
Pancreas (2) Spleen (3)
Fat (5) Pancreas (4)
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3.4 Whole body weights and organ weights
In section 1.3 mice were culled for organ and blood analysis at 9-10 months. A. Ward also 
culled mice at 4 weeks and 8-12 weeks of age. Selections of organs were weighed from 
both of these groups of mice (divided into male and female) and blood samples were sent 
for glucose analysis from the mice culied at 9-10 months.
3.4.1, 4 week and 8-12 week data
Whole body weights were measured in both female and male mice at 4 weeks and at 8-12 
weeks (Figure 13 and 14). Stastical analysis showed no significant difference between 
AU2hetM/p53wt and AU2hetP/p53wt (p= 0.352) so they were added together on the 

























Figure 13. Female whole body weights at 4 weeks and 8-12 weeks of age.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene is represented by heterozygous expression as 





4 weeks 8-12 weeks
Age at dissection
i  U 2hetM /p53het 
I U 2hetP /p53het 
I U2wt/p53null 
I U 2hetP/p53w t 
3 U2hetM /p53null 
] U 2hetP/p53null
^  U 2w t/p53het 
^  U2wt/p53wt
Figure 14. Male whole body weights at 4 weeks and 8-12 weeks of age.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR! by U2hetP and w ild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
Female and male heart weights are shown in Figure 15 and Figure 16. At 4 weeks the 
genotype with the heaviest hearts in the females were theAU2wt/p53wt mice and with the 
lightest hearts were the AU2hetP/p53null mice. At 8-12 weeks there was no real difference 
in the heaviest heart weights between the AU2hetP/p53wt and the AU2wt/p53wt groups. 
The lightest hearts were in the AU2wt/p53null group but only just. In the male group at 4 
weeks the heaviest hearts were from the AU2hetP/p53null and the lightest hearts were from 
the AU2hetM/p53wt group. At 8-12 weeks the heaviest hearts were in the 
AU2hetP/p53null group and the lightest hearts were in the AU2hetP/p53wt group.
Female and male liver weights are shown in Figure 17 and 18 respectively. At the 
4-week stage, the female genotype with the heaviest livers were the AU2wt/p53hets and 
with the lightest livers were the AU2hetM/p53null mice. At the 8-12 week stage this 
changed to the AU2wt/p53wt mice having the heaviest livers and the AU2wt/p53het mice 
having had the lightest livers. In the male group at 4 weeks the heaviest livers were found
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in the AU2hetP/p53null mice and the lightest in the AU2hetM/p53null mice. At the 8-12 
week stage this was maintained.
Female and male kidney weights are shown in Figure 19 and 20 respectively. At 4 
weeks in the female group the heaviest kidneys were found in the AU2wt/p53wt mice and 
the lightest in the AU2hetM/p53null mice. At 8-12 weeks the heaviest kidneys were in the 
AU2hetP/p53wt mice and the lightest in the AU2wt/p53het mice. In the male group the 
heaviest kidneys were in the AU2hetM/p53het mice and the lightest in the 
AU2hetP/p53null mice. At the 8-12 week stage both the AU2hetP/p53het and 
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mm U2hetlWp53wt 
mm U2hetP/p53wt 
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U2wt/p53null
Age at dissection
Figure 15. Female heart weights at 4 weeks and 8-12 weeks of age.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 









■ ■  U2hetlWp53wt 
■  U2hetP/p53wt 
f = l  U2hetM/p53null 
QHD U2hetP/p53null 
^  U2wt/p53het 
^  U2wt/p53wt 
U2wt/p53null
Figure 16. Male heart weights at 4 weeks and 8-12 weeks of age.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
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Figure 17. Female liver weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
Figure 18.







□ m i U2wl/p53het 
U2wt/p53wt 
U2wt/p53null
Figure 18. Male liver weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
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Figure 19.
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Figure 19. Female kidney weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
Figure 20.
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Figure 20. Male kidney weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
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Female uterus weights are shown in Figure 21. At 4 weeks, the heaviest uterus was in the 
AU2hetM/p53wt genotype and the lightest uterus was in the AU2hetM/p53null genotype. 
At 8-12 weeks this changed to the heaviest uterus being in the AU2hetP/p53wt group and 
the lightest uterus in the AU2wt/p53null group of mice.
Male testes weights are shown in Figure 22. At the 4-week stage, the heaviest testes 
were found in the AU2hetM/p53null mice and the lightest testes were found in the 
AU2hetP/p53null mice. At 8-12 weeks the heaviest testes were found in the 
AU2wt/p53null mice and the lightest testes in the AU2hetM/p53null mice.
Female and male thymus weights are shown in Figure 23 and Figure 24 respectively.
In the female mice dissected at 4 weeks the heaviest thymus weight were observed in the 
AU2hetM/p53null mice and the lightest thymus weights were observed in the 
AU2wt/p53wt mice. At 8-12 weeks the heaviest thymus weight observed were from the 
AU2wt/p53null mice and the lightest thymus weights were from the AU2wt/p53het mice.
In the male mice, the heaviest thymus weights observed at 4 weeks was in the 
AU2hetP/p53null mice and the lightest thymus weight was observed in the 
AU2hetM/p53null mice. At 8-12 weeks, the heaviest thymus weight observed remained in 
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Figure 21. Female uterine weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
Figure 22.
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Figure 22. Male testicular weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
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Figure 23. Female thymus weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
Figure 24.
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Figure 24. Male thymus weights at 4 weeks and 8-12 weeks.
A maternal deletion of DMR1 was represented by U2hetM, a paternal deletion of DMR1 by U2hetP and wild 
type DMR1 expression by U2wt. The status of the p53 gene was represented by heterozygous expression as 
p53het, wild type expression as p53wt and a full knock out by p53null.
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3.4.2: 10 months organ weights and blood analysis.
At 9-10 months of age, whole body and organ weights were taken from 44 mice in the 
experimental group. Four genotypes were represented in this group, AU2hetM/p53null, 
AU2hetM/p53het, AU2wt/p53null and AU2wt/p53het. Female and male whole body 
weights, and female and male liver weights are shown in Figure 26. In the female whole 
body weights graph the heaviest genotype was the AU2wt/p53null group and the lightest 
was the AU2hetM/p53het group. This was also true for the female liver weights. The 
AU2wt/p53het group. Again this was maintained in the male livers.
In Figure 27 female and male spleen and brain weights are shown. The heaviest 
female spleen was observed in the AU2wt/p53null genotype and the lightest spleen was 
observed in the AU2hetM/p53het genotype. This pattern was repeated in the female brains. 
The heaviest male spleen was observed in the AU2wt/p53null genotype and the lightest 
male spleen was observed in the AU2wt/p53het genotype, which was again seen in the 
male brains.
Figure 28 shows female ovarian fat pad weights with the AU2wt/p53null mice 
having the heaviest fat pads and the AU2wt/p53het mice having the lightest fat pads. In 
Figure 29 which shows the male testicular fat pad weights the heaviest observed were in 
the AU2wt/p53null mice and the lightest were in the AU2hetM/p53null mice.
Figures 30 and 31 show female and male renal fat pad weights. In the females the 
heaviest renal fat pads were observed in the AU2wt/p53null mice and the lightest were in 
the AU2hetM/p53het mice. In the males, the heaviest renal fat pads were observed in the 
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Figure 26. Female and male whole body and liver weights.
Column A represents the AU2hetM/p53null genotype, column B represents the AU2hetM/p53het genotype, 
column C represents the AU2wt/p53null genotype and column D represents the AU2wt/p53het genotype in 
all four graphs. AU2hetM is a maternal deletion of DMR1 and AU2wt is wild type DMR1. A full p53 knock 
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Figure 27. Female and male spleen and brain weights.
Column A represents the AU2hetM/p53null genotype, column B represents the AU2hetM/p53het genotype, 
column C represents the AU2wt/p53null genotype and column D represents the AU2wt/p53het genotype in 
all four graphs. AU2hetM is a maternal deletion of DMR1 and AU2wt is wild type DMR1. A full p53 knock 
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Figure 28. Female ovarian fat pad weights.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
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Figure 29. Male testicular fat pad weights.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
knockouts of the p53 gene and p53hets are heterozygous for p53.
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Figure 30.
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Figure 30. Female renal fat pad weights.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
knockouts of the p53 gene and p53hets are heterozygous for p53.
Figure 31.
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Figure 31. Male renal fat pad weights.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
knockouts of the p53 gene and p53hets are heterozygous for p53.
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In both the female and male mice the organs were expressed as a percentage of the total 
body weight to detect any organs that were proportionally larger or smaller in any 
particular genotype (Figure 32 and Figure 33). In the female mice the uterine fat pads were 
the highest percentage of the total body weight whereas in the male mice the liver had the 
highest percentage, with the testicular fat pads coming second. No single genotype had 
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Figure 32. Female organs expressed as a percentage of the total body weight.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
knockouts of the p53 gene and p53hets are heterozygous for p53. The organs were the brain, liver spleen, 
uterine fat pads (Gen. fat) and renal fat pads (Ren. fat).
Figure 33.
o "  SI
co .S> 
CO Q )
J2 *SI >*o -o
I f








n a i l I I m A t
Brain Liver Spleen Gen. fat Ren. fat 
Male organs
Figure 33. Male organs expressed as a percentage of the total body weight.
U2hetM is a maternal deletion of DMR1 and U2wt are wild type expression of DMR1. P53nulls are full 
knockouts of the p53 gene and p53hets are heterozygous for p53. The organs were the brain, liver spleen, 
testicular fat pads (Gen. fat) and renal fat pads (Ren. fat).
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3.4.3 Growth curves.
Over a period of 12 months, all 92 mice were weighed on a weekly basis. The weights 
were recorded and this was also when tumours were detected and weight loss noted in any 
of the mice. Figure 34 shows the growth curve of some of the female mice. Not all 
genotypes were added to the curve as there was no significant differences in growth rate.
Figure 35 shows the rate of growth of the male mice over the same period and 















Figure 34. Effect of genotype on growth of female mice.
Maternal deletions of DMR1 are represented by U2hetM, paternal deletions by U2hetP and wild type DMR1 
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Figure 35. Effect of genotype on the growth of male mice.
Maternal deletions of DMR1 are represented by U2hetM, paternal deletions by U2hetP and wild type DMR1 
by U2wt. Mice heterozygous for p53 are represented by p53het, wild type p53 by p53wt and knock outs by 
p53null.
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3.4.4 Glucose levels analysis
The aortic blood samples taken from the mice culled for analysis were sent off and the 
glucose levels measured (Figure 36.). In both sexes, the genotypes with the highest 
circulating glucose levels were the AU2wt/p53null mice.
The livers from some of these mice were stained with PAS to detect gycogen in the 









Figure 36. Average glucose levels in both sexes.
Maternal deletions of DMR1 are represented by U2hetM and wild type DMR1 by U2wt. Mice heterozygous 
for p53 are represented by p53het and knock outs by p53null.
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Figure 37. Sections of livers taken from mice culled for analysis of organ weights.
The left panel was stained with H+E, the right panel with PAS. The numbers in brackets are numbers 
assigned to the organs for identification purposes.
3.3 Discussion:
The aims of this study were to investigate the combined effect of p53 tumour suppressor loss 
and model up-regulation of Igf2 expression knockout mice. p53 null and Igf2 AU2 alleles 
were intercrossed. From this cross 96 progeny were studied, primarily in order to correlate 
tumour incidence within this group.
3.3.1: mice that died of unknown causes
Of the 96 mice studied, 14 died without showing any sign of ill health. When dissected 
(where possible) no obvious cause of death was found and no significant weight loss had been 
detected prior to death. The most prevalent genotype represented in this group were 
AU2hetM/p53het mice (three of these mice died of unknown causes). In addition, one mouse 
of genotype AU2hetM/p53wt, making 4 mice in total, which had a maternal deletion of 
DMR1. There were 45 mice in total in this group that had a maternal deletion of DMR1, so 4 
out of 45, only represents 8%, of mice dying for unknown reasons and it is unclear what the 
significance of maternal deletion of the normally silent DMR1.
One AU2hetP/p53het mouse and 3 AU2hetP/p53null mice died of unknown causes 
resulting in a total of 4 mice with a paternal deletion of DMR1 in this group. There were 16 
mice in total that had a paternal deletion of DMR1 and 4 out of 16 (25%) is a large proportion 
of this genotype dying of unknown reasons. A paternal deletion of the normally expressed 
DMR1 appears to have an effect on the death rate of these mice.
Six mice in total which were wild types for DMR1 died of unknown causes. There 
were 25 mice in total that were wild type for DMR1 and 6 out of 25 (>33%) is a significant 
proportion of this genotype to die of unknown causes. Wild type DMR1 mice would not be 
expected to die for unknown reasons and it is possible that in this genotype the p53 status has 
a significant effect on the death rate in this group. However 4 of these mice are heterozygous 
for p53 and 2 are p53 knock outs both of which are linked with cancer development and early 
death in mice (Donehower 1992; Clarke 1993). Eight mice that were heterozygous for p53 
out of 52 (15%) died of unknown causes, five mice that were p53 knock outs of 34 (14%) 
died, and only one p53wt mouse out of 10 (10%) died of unknown reasons. The p53wt mouse 
was as mentioned above, was AU2hetM, which could have been the cause of death. All of 
these percentages are significant numbers of a particular genotype to die for unknown 
reasons.
The age at death of these mice ranged from 3 to 19 months with the majority dying 
after 12 months of age. Loss of DMR1 does not appear to bring forward or delay that age at
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death observed in mice with altered p53 in other experiments (Clarke 2003). Previous 
experiments showed p53 mutant mice dying at 11 months on average.
3.3.2: Mice that lost more than 10% of their total body weight in one week.
Mice that had lost greater than 10% of their total body weight in one week were culled 
and dissected in an attempt to explain the sudden weight loss. Ten mice in total out of the 82 
remaining mice, (i.e.: exclusively those that died of unknown causes), showed this rapid 
weight loss. Seven of these ten mice had thymus tumours, one had an enlarged spleen and two 
mice had no detectable pathological change associated with the weight loss.
Pathological analysis of some of these abnormal organs showed a malignant 
lymphoma for thymus no.l (AU2hetM/p53het) and thymus no. 5 (AU2hetM/p53null) and an 
enlarged cellular structure for spleen no. 19 (AU2wt/p53null).
Thymus tumours are not unusual for mice with altered p53 and an enlarged spleen can 
be an indication of infection rather than any genetic cause. Research carried out by 
Donehower (Donehower 1992) showed that the most frequently observed tumours found in 
p53-altered mice were malignant lymphomas usually in the thymus and other visceral organs 
including the spleen.
The most prevalent genotype among of mice that lost >10% of their total body weight 
in one week, were the AU2wt/p53null (71%)mice which is to be expected as p53 null mice 
are most likely to develop lymphomas. In the analysis carried out by Donehower 26 out of the 
30 mice analysed were p53nulls found to have lymphomas.
The mouse that had an unknown reason for their weight loss was p53wt .It is possible 
that the weight loss was not due to tumour formation but some other etiological factor.
Most of the weight loss in these mice was detected at ages 5 to 10 months, with most 
of the thymus tumours detected at 5 to 6 months of age. The enlarged spleen was detected at 6 
months and the unattributed weight loss occurred at 10 months. P53 null mice are prone to 
neoplasm development at 6 months of age (Donehower 1992), and in this study 7 out of the 
10 mice with weight loss were p53null mice.
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3.3.3: Tumour development.
Nine mice out of the 96 mice studied developed obvious abnormalities in the absence of a 
greater than 10% body weight loss. Out of the six abnormalities found (spinal, lymph, facial, 
subcutaneous, vaginal and leg) most were tumours that affected the lymph nodes. The range 
of tumours types was more extensive than in the mice with a detectable weight loss.
The genotypes of the abnormalities were mostly AU2hetM/p53het. The subcutaneous tumour 
was also a p53het but with a paternal deletion of DMR1. Only one of the lymph node tumours 
was AU2hetP/p53null. Lymph node tumours have been detected in previous studies 
(Donehower 1992),(Clarke 2003) and are not unusual in mice with altered p53 expression. 
Pathology reports on lymph node tumour no.7 and no.9 showed probable malignancy, with 
multinuclear giant cells.
The facial tumour was unusual with no previous facial tumour mentioned in other 
similar studies. However, it is likely that this was a sarcoma, and sarcomas are common in 
p53 mutant mice.
Subcutaneous tumour no.2 was diagnosed as a mammary adenocarcinoma. The 
Donehower 1992 study included one mouse with a mammary adenocarcinoma in the p53 null 
genotype, and in this study the same tumour occurred in the AU2hetP/p53het group. With 
only one mouse developing a tumour of this type it is not possible to ascribe any significance 
in the different genotype of this mouse and that of the Donehower (1992) study.
Genital tumours have been detected in previous studies (ovarian sarcomas, ovarian 
choriocarcinmoa, Leydig-cell tumours of the testis and embryonal carcinoma of the testis). 
However tumours of the vagina or labia are not mentioned in these studies so this tumour 
could possibly be outside the typical tumour spectrum. However it did not result in dissection 
at an unusual age and it was in a tumour-associated genotype (AU2hetM/p53het).
The leg abnormality found in this group did not reveal a tumour. The mouse had 
difficulty walking but when analysed no source was found. This could have been to a physical 
injury rather than a physiological or genetic abnormality.
Within this group of mice that developed spontaneous abnormalities there was no 
statistical difference between the genotypes regarding the ages at which they were culled. The 
mice were culled between the ages of 12 to 18 months. This was older than the mice that 
showed a detectable weight loss. When compared statistically there was a significant 
difference (p= 0.0039)(Mann-Whitney analysis). These mice mostly developed lymphomas 
whereas the weight loss group developed thymus tumours. It seems that weight loss can be 
associated with thymus tumour development and can lead to earlier detection of this tumour
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type. Lymphomas do not seem to induce significant weight loss and so the mice are older by 
about six months when a tumour finally becomes obvious.
3.3.4: End of experiment analysis
When the mice that had lost >10% of their body weight, the mice that had developed 
spontaneous tumours and the mice culled for analysis of organ weights and blood glucose 
levels had been removed there were 19 mice left that were culled and dissected at the end of 
the experiment. Upon dissection, some tumours were found (Figure 11.).
Enlarged seminal vesicles were found in one mouse (seminal vesicles no. 11) which 
were diagnosed as a spindle cell sarcoma composed of fibroblastic cells. Again, these were 
seen in the Donehower (1992) study and are therefore not unusual for p53-altered mice. The 
same mouse also had a facial tumour (no. 11), which was described as a hyperkeratinized 
squamous cell papilloma. This was the only mouse in which two obvious and separate 
tumours were detected.
One ovarian tumour (no. 12) was diagnosed as two different lesions, an endometrial 
stromal sarcoma and a hysticytic sarcoma. The mouse was 20 months old when culled. 
Ovarian tumour (no. 13) was diagnosed as a hemangioma with thrombus formation and the 
mouse was 20 months old when culled. A uterine anomaly (no. 16) was thought likely to be a 
uterine glandular polyp. In the Donehower (1992), study a chimeric mouse at 14 months 
developed osteogenic sarcoma and a choriocarcinoma. This suggests that tumours of the 
female reproductive organs are complex and usually develop much later than the previously 
discussed thymus and lymph node tumours.
3.3.5 Genotypes of tumours
Some of the tumours were genotyped independently of the mice they were removed from and 
the results were given in Table 2. Two tumours appeared to lose a p53 allele, an ovarian 
tumour (no. 13), which went from AU2hetM/p53wt to p53het (allele loss), and a thymus 
tumour (no.l), which went from AU2hetP/p53het to p53null. The ovarian tumour was 
detected at 20 months which is late in development, but the mouse was wild type and it may 
take longer for mutations to occur which change p53wt to p53het than to change p53het to 
p53null.
The thymus tumour (no.l) was detected earlier than 20 months. This fits with Knudson’s and 
Strongs two hit model of carcinogenesis. This states that both alleles of a gene must be lost in
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1order for cancer to develop. A mouse that is heterozygous for p53 already has a predisposition 
to tumour formation and only requires one more mutation to develop cancer. Also this mouse 
developed cancer early at six months, which again fits with this model, as mice that had two 
intact copies of the p53 gene would take longer to develop the double allele loss required for 
tumour formation and so, it would occur later in development.
Two of the tumours appeared to lose the mutant p53 allele, ovarian tumour (no. 12) 
went from AU2hetM/p53het to p53wt and uterine tumour (no. 16) went from AU2hetM/p53het 
to p53wt.
3.3.6: Mice culled for analysis
In total 44 mice were culled for organ weight and blood glucose analysis. The ages at death 
were between 9 and 10 months of age. Sections were taken of the organs that were weighed 
and some of them were stained with H+E (see Figure 12). No abnormalities were found in 
these organs.
3.4.1: 4 week and 8-12 week data
Cohorts of mice were culled at 4 weeks and 8-12 weeks of age and their organs were 
weighed. Mice were also weighed at 9-10 months of age, their dissected organs weighed, and 
their blood analysed for glucose levels.
At four weeks of age in the female mice (Table 1) the genotype with the heaviest 
organ the majority of the time was the AU2wt mice, whether they were p53het or p53wt. This 
result agrees with the expected answer as maternal deletion of DMR1 had no effect on organ 
weight and paternal deletion of DMR1 led to smaller pups at birth that caught up with their 
wild type littermates postnatally (Constancia 2000). It appears that at 4 weeks AU2hetP mice 
had not quite caught up with AU2wt mice.
The genotypes associated with the lightest organs at 4 weeks were the 
AU2hetM/p53null mice. A maternal deletion of DMR1 does not increase organ weight and 
out of the three possible states of Igf2, maternal deletion of DMR1 could lead to lightest 
organ weights.
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At 8-12 weeks in the female mice the heaviest organs were evenly spread between 
AU2hetP and AU2wt genotypes but the majority were p53wt. The accelerated growth seen in 
AU2hetP mice after birth appears to have brought these mice to the same weights as the 
AU2wt mice. The lightest organs at 8-12 weeks were associated with AU2wt/p53het mice. All 
of the lightest organs were AU2wt which could suggests that the AU2hetP mice have 
overtaken the AU2wt mice.
Organ (9) 4 wk. heaviest 4 wk. lightest 8 wk. heaviest 8 wk. lightest
Whole body AU2wt/p53het AU2hetM/p53null AU2het/p53wt AU2wt/p53wt
Heart AU2wt/p53wt AU2hetP/p53null AU2wt/p53wt AU2wt/p53null
Liver AU2wt/p53het AU2hetM/p53null AU2wt/p53wt AU2wt/p53het
Kidney AU2wt/p53wt AU2hetM/p53null AU2hetP/p53wt AU2wt/p53het
Uterus AU2hetM/p53wt AU2hetM/p53null AU2hetP/p53wt AU2wt/p53null
Thymus AU2hetM/p53null AU2wt/p53wt AU2wt/p53null AU2wt/p53het
Table 1. Summary of heaviest and lightest organ weights at 4 weeks and 8 weeks of age in female mice.
AU2 wt are mice with wt DMR1, AU2hetM have a maternal deletion of DMR1 AU2hetP have a paternal 
deletion of DMR1. p53het are mice that are heterozygous for p53, p53 null are p53 knockout mice and p53wt are 
mice with wild type expression of p53.
In the male mice (Table 2) at 4 weeks of age, the heaviest genotypes were the 
AU2hetP/p53null mice. The accelerated growth associated with paternal deletions of DMR1 
appears to be evident here, to the extent that the AU2hetP mice are heavier than their AU2wt. 
The lightest genotypes were the AU2hetM/p53null mice. However, all of these mice were 
p53nulls.
At 8-12 week stage of development, the mice with the heaviest organs were the 
AU2hetP/p53null mice. Again, the catch-up effect of paternal deletion of DMR1 seems to be 
out performing the AU2wt mice. The lightest organs were evenly distributed between the 
AU2hetP/p53wt and AU2hetM/p53null mice.
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Organ (c?) 4 wk. heaviest 4 wk. lightest 8 wk. heaviest 8 wk. lightest
Whole body AU2hetP/p53het AU2hetM/p53null AU2hetP/p53null AU2hetP/p53wt
Heart AU2hetP/p53null AU2hetM/p53wt AU2hetP/p53null AU2hetP/p53wt
Liver AU2hetP/p53null AU2hetM/p53null AU2hetP/p53null AU2hetM/p53null
Kidney AU2hetM/p53null AU2hetP/p53null AU2wt/p53het AU2hetM/p53null
Testes AU2hetM/p53null AU2hetP/p53null AU2wt/p53null AU2hetM/p53null
Thymus AU2hetP/p53null AU2hetM/p53null AU2hetP/p53null AU2hetP/p53wt
Table 2. Summary of heaviest and lightest organ weights at 4 weeks and 8 weeks of age in male mice.
AU2 wt are mice with wt DMR1, AU2hetM have a maternal deletion of DMR1 AU2hetP have a paternal 
deletion of DMR1. p53het are mice that are heterozygous for p53, p53 null are p53 knockout mice and p53wt are 
mice with wild type expression of p53.
3.4.2: 9-10 months organ weight analysis
In the female mice at 9-10 months (Table 3) of age the heaviest genotype was the 
AU2wt/p53null mice; illustrating that wild type DMR1 mice have heavier organs than mice 
with altered DMR1 expression. The lightest organs were associated with AU2hetM/p53het 
mice in the majority of mice analysed. A maternal deletion of DMR1 leading to altered Igf2 
expression leads to lighter organs than those observed in AU2wt mice.
Organ (9) Heaviest genotype Lightest genotype




Ovarian fat pad AU2wt/p53null AU2wt/p53het
Renal fat pad AU2wt/p53null AU 2hetM/p5 3 het
Table 3. Summary of heaviest and lightest organ weights at 9-10 months of age in female mice.
AU2 wt are mice with wt DMR1, AU2hetM have a maternal deletion o f DMR1 AU2hetP have a paternal 
deletion of DMR1. p53het are mice that are heterozygous for p53, p53 null are p53 knock-out mice and p53wt 
are mice with wild type expression of p53.
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In the male mice the heaviest organs were associated with AU2wt/p53null mice as was 
observed in female mice at the same age. Unlike what was seen in females, the lightest organs 
were observed in AU2wt/p53het mice rather than AU2hetM/p53het mice observed in female 
mice.
Organ (c?) Heaviest genotype Lightest genotype




Testicular fat pad AU2wt/p53null AU2hetM/p53null
Renal fat pad AU2wt/p53null AU2hetM/p53null
Table 4. Summary of heaviest and lightest organ weights at 9-10 months of age in male mice.
AU2 wt are mice with wt DMR1, AU2hetM have a maternal deletion of DMR1 AU2hetP have a paternal 
deletion of DMR1. p53het are mice that are heterozygous for p53, p53 null are p53 knockout mice and p53wt are 
mice with wild type expression o f p53.
When the organ weights were expressed as a percentage of whole body weight, in the females 
the heaviest genotypes were the AU2wt/p53null mice and in the male the same was true 
except for the liver weights where the AU2hetM/p53null mice had the heaviest livers.
In the female mice, the genital fat pad weights took up the largest percentage of the total body 
weight, but in the males the livers took up the largest percentage followed by the genital fat 
pad weights.
3.4.3Growth curves
In the female mice the steepest growth curve was seen in the AU2wt/p53null mice, which 
grew bigger than the AU2hetM/p53wt mice in the final 2 months of this study. The smallest 
mice were the AU2hetP/p53wt mice. In the male mice the steepest growth curve was seen in 
the AU2wt/p53null mice also, which overtook the AU2wt/p53het mice 4 months before the 
end of the study. The lightest mice were the AU2hetP/p53het mice. Paternal deletions of 
DMR1 result in smaller mice and DMR1 wild type mice are the largest in this group. The 
standardised average expected weight for a non-transgenic mouse at 12 months is around 35g
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which is slightly higher than the female weight observed in this study and slightly lower than 
he observed male weights discussed here.
3.4.4 Glucose analysis
The results from the glucose analysis are shown in Figure 36. In both the female and male 
mice, the highest glucose levels were found in the AU2wt/p53null mice. These mice also had 
the heaviest organs and the highest percentages body fat. In addition, these mice had the 
steepest growth curves.
These mice which have high body fat ratios and high circulating glucose levels may 
also have relatively low circulating levels of Igf2. AU2wt mice would be expected to have 
higher circulating levels of Igf2 than AU2hetM mice do, as there was no deletion of DMR1 
(Rogler 1994) (Ward 1994). To further analyse the effect on energy storage in these mice a 
selection of liver sections were stained with PAS, which stains glycogen purple. The darkest 
purple staining can be seen in liver (5), which was from a AU2wt/p53null mouse and had the 
most glycogen on the liver.
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Chapter four: Analysis of transgenic mice and transient transfections
4.1.1 Transgenics
A transgenic organism is one derived from a cell in which the genome has been 
modified by the addition of exogenous DNA. In these experiments, two types of reporter 
gene were used in constructs that were injected into mouse embryos. The luciferase 
reporter gene allowed quantification of the expression of the transgene and the beta- 
galactosidase (lacZ) reporter gene allowed qualitative analysis of transgene expression.
A transgenic organism can be created in a number of ways such as nuclear 
injection, viral infection and transfection. Yeast and plant cells can be transfected (e.g. by 
electroporation) with DNA, having used enzymes to remove their outer coating. The cells 
(spheroplasts) are then capable of taking in the exogenous genes. Yeast, plant and animal 
cells can be electroporated, which makes their membranes permeable to DNA in their 
medium (Loadish 2000). Initial experiments were carried out on the yeast Saccharomyces 
cerevisiae using plasmids. Yeast artificial chromosomes (YAC) were developed which had 
a centromere; telomeres and autonomous replication sequences (ARS) added and were 
linearised. This allowed the YACs to be treated more like yeast chromosomes when the 
cells divided and were passed onto the next generation of cells (Griffiths 1999). This 
ability that yeast has to take up foreign DNA is useful in creating knockout yeast cells. A 
mutant allele of a particular gene can be added to the cells, which has been altered in such 
a way as to not produce a protein. Any cells with this mutant gene will not be able to 
produce by homologous recombination, the protein of interest and so are considered 
knockouts (Loadish 2000).
To create transgenic plants the vector used most often came from the bacteria 
Agrobacterium tumefaciens which caused crown gall disease in plants (plant tumours). 
When the transgene was spliced into this Ti plasmid (tumour inducing) and this was 
introduced to the plant the transgene was integrated into the plant genome (Griffiths 1999).
In animals, transgenesis has been used to examine development and disease mostly 
in Drosophila, nematode worms (Caenorhabditis elegans) and mice. Transgenic 
Drosophila were created using a reporter gene (Section 4.1.2) and heat shock genes 
incorporated into the transgene construct. The flies were allowed to reach the appropriate 
stage of development and then were heat shocked to activate the transgene. The flies were 
then assayed to examine were the gene was expressed (Griffiths 1999). An example of an 
aberrant phenotype created using transgenics is with the gene Antennapedia (Antp) which
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affects leg development. When this was introduced to the head region of Drosophila, a leg 
developed at the front of the head instead of antenna (Loadish 2000).
Transgenic mice are usually created by injecting foreign DNA into either the male 
or female pronucleus {Gordan, 1980 #68}. The resulting mice are either transgenic (the 
transgene is present in every cell) or mosaic (the transgene is present in a subset of cells). 
The zygote can then be transferred into the uterus of a host mouse and develops as normal. 
Where the transgene inserts into the genome is essentially random and there are usually 
multiple copies present at a single integration site. Up to 30% of offspring can carry the 
transgene which, when genotyped and identified, can be backcrossed to create 
heterozygous and homozygous mice which are positive for the transgene.
Knock out mice are created in a slightly different manner. A specific deletion 
cannot be introduced directly into an organism’s germ cells so a method of deleting DNA 
in cells and combining those cells with wild type blastocyst stage embryos was developed. 
Embryonic stem (ES) cells, derived from the inner cell mass of the blastocyst are mutated 
and the deletion of the gene of interest is induced. Having checked for the deletion these 
mutated ES cells are added to wild type blastocyst preimplantation embryo cells, which are 
then transferred into host mothers. The resulting offspring are called chimeras as they have 
tissues derived from both wild type cell and the mutant ES cells. The offspring are 
genotyped and backcrossed to determine if the transgene has been incorporated into the 
germ cells of the mice and therefore can be passed on to create a knock out line of mice. 
The creation of knock out mice is useful in determining the role of genes in development, 
or for instance in tumour formation as the effect of the loss of the gene can be examined 
(Loadish 2000). The Cre-lox system has also been used to create knock out mice. LoxP 
sites are sites of DNA recombination and Cre is an enzyme that can catalyse recombination 
between these sites. LoxP sites are placed to flank the gene of interest in one mouse, and a 
Cre transgene under the control of a specific promoter is introduced into another mouse. 
When both of these transgenic mice are mated the Cre will induce recombination between 
the loxP sites disrupting the target gene at the sites of Cre expression (Loadish 2000).
4.1.2 Reporter genes
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So-called reporter genes can be used for ready detection of transgenic activity. 
These reporter genes are easy to assay against endogenous gene expression and can be 
detected quantitatively or qualitatively. Two commonly used reporter genes are LacZ and 
luciferase. The lacZ gene codes for p-galactosidase, which breaks down lactose. It also has 
the ability to break down X-Gal (5-bromo-4-chloro-indolyl-P, D-galactosidase) to 5- 
bromo-4-chlorindigo, which is detectable as it is blue in colour. This allows transgene 
expression patterns to be visualised and the expression can also be measured using a 
colorimeter. However this is not the most sensitive system available for quantative 
analysis. Another reporter gene is luciferase which uses luciferin as substrate and in the 
presence of ATP emits light that can be used as a measurement of transgene expression. 
Luciferin is not only quantifiable it is inexpensive and does not require the use of 
radioisotopes for detection. It can also be used to visualise expression patterns but requires 
luminescence sensitive imaging equipment, which is more expensive than the LacZ system 
and does not provide information at such high resolution.
4.1.3 Transient transfections
The process in which exogenous DNA is introduced into cells is called transfection. 
Various methods of gene transfer are used for the purposes of expressing a protein. It is 
useful for studying biochemical feature of proteins, antisense inhibition of protein 
expression, transcription-regulation of regions of genes using promoter-reporter fusions 
and the function of non-coding RNA. The advantages of transient transfection are that 
there is usually a high level of gene expression in the cell and it is quick and easy. Some 
disadvantages are that the technique requires a large amount of plasmid DNA and there is 
high variability in the numbers of cells taking up the exogenous DNA (Phillips 1999).
Transient transfections were carried out in this study using the luciferase reporter 
gene (Section 4.1.2). In vitro experiments are useful for cheaper and less complicated 
analysis of genes in particular cell lines, but do not give as comprehensive a result as in 
vivo studies. In this case transient transfections were used as a comparison with a 
transgenic mouse study. The major difference between using transgenic and transient 
transfections is that transgenics give results in a whole organism (where ever the promoter 
is expressed), whereas tissue culture can only give results in the cell line used, which 
normally are only one cell type, under more artificial conditions. An advantage is that 
where a construct may cause embryonic lethality in a mouse, in a cell line it may not cause
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any cell damage if harvested after 24-48 hours and so some analysis can be carried out. 
The same luciferase reporter gene technology was used to assay results as was used in the 
transgenic mice.
The luciferase reporter gene was also used in experiments analysing DMR2 
(Murrell 2001). Constructs using luciferase and various elements of Igf2 were made to 
determine the minimum sequences required to increase expression in a methylation 
dependent manner. Methylation of Hhal sites reduced expression 5-fold from the P3 
promoter suggesting that the methylated region of Ig/2 DMR2 is required for maximal Ig/2 
expression.
4.1.4 Previous analysis of 7g/2 and H19
Experiments utilising LacZ have been carried out on transgenic mice in which the 
Igf2 coding region was interrupted by LacZ within a 130kb YAC (yeast artificial 
chromosome) construct, also containing the H19 gene in order to examine paternal and 
maternal differences in transmission of Ig/2 and H19 in the embryos at El 3 (Ainscough 
1997). This 130kb YAC was shown to contain the elements necessary to visualise 
appropriate mesodermal and endodermal expression of Ig/2. This YAC was introduced to 
mice lacking endogenous H19 and at e l4.5, expression was seen in the liver and skeletal 
muscle, especially in the tongue, and in the epithelial linings of the gut, kidneys and lungs. 
Expression was not seen in the cardiac and smooth muscle cells indicating that elements 
outside the YAC were required to emulate endogenous H19 expression normally seen in 
these cells (Ainscough 2000). When the extra-embryonic tissues were examined 
expression was seen in the yolk sac but not in the placenta indicating that the placental Igf2 
enhancers lie beyond the region covered by the YAC (Ainscough 2000).
Previously luciferase expressing transgenic mice were used to quantify the 
expression for Ig/2 regulating elements in embryos and one-day-old mice (Ward 1997). 
Igf2, the P3 promoter and the luciferase gene were joined together in a construct and 
injected into embryos and the luciferase levels were measured in the liver and the brain.
The results showed that DMR1 has an inhibitory effect on Igf2 expression in the liver, the 
DMD enhances Igf2 expression in the brain and the H I9 promoter inhibits Ig/2 expression 
in the brain (Dell 1997). In other experiments constructs contained a combination of the 
H19 promoter, H19 enhancer, DMR1 and the CCD combined with luciferase and the P3 
promoter. The expression levels of Igf2 in the placenta and the yolk sac was examined to
79
investigate the link between down regulation of Igf2 after birth and the glucocorticoid 
surge present at the same stage (Dell 1997).
4.1.5 Aims:
The purpose was to examine the effect of DMR1 had on Igf2 expression and this 
was examined in three ways: firstly, transgenic mice expressing the luciferase transgene 
were examined to see expression levels in various organs. The constructs had different 
elements from the Igf2-H19 gene region present to analyse the effects each element had on 
transgene expression. Luciferase was measured in selected organs to determine relative 
levels of expression. A comparison was made between male and female transmission of the 
transgenes in order to examine any potential expression level differences that might be the 
result of genomic imprinting. Also, methylation patterns associated with the transgene 
were analysed in these same organs to determine if there was any correlation between 
transgene expression from male and female inherited transgenes and the subsequent 
methylation patterns observed from these mice. Expressions from the different constructs 
were then compared in different lines of mice to see whether the presence of DMR1 
increased or decreased transgene expression.
The second set of experiments carried out was the creation and examination of 
LacZ expressing transgenic mice. Constructs with or without DMR1 were injected into 
fertilised embryos and the mice subsequently stained to visualise transgene expression. A 
comparison was made between these mice to see the effect DMR1 had on expression 
patterns and any differences or similarities in expression were noted.
Thirdly, tissue culture cells were transfected with luciferase expressing constructs 
and the expression levels were measured and comparisons were made between the 
different constructs. The constructs were then methylated to analyse the effect that 
methylation had on expression from constructs containing DMR1. Any correlation 




Reporter gene constructs used in transgenic mice and in transient transfection experiments 
are shown in Figure 1.
4.2.1 Luciferase expression in mice carrying luciferase transgenes
4.2.1.1 Transgenic expression in the Eva and Elvis lines at e!4.5
In the Eva line of mice luciferase expression levels were highest in the body and 
lowest in the head (Figure 2). In Elvis mice however luciferase expression was highest in 
the head and lowest in the yolk sac (Figure 3). In both lines there was higher average 
expression in the embryo proper than in the extra embryonic tissues. In the comparison 
between male and female transgene transmission in the mice expressing construct E no 
statistically significant difference was found between the sexes.
4.2.1.2 Transgenic expression in the Titus, Tilly and Tracy lines at e!4.5
In the Titus pups highest transgene expression was observed in the body and lowest 
expression was observed in the yolk sac (Figure 4). In Tilly litters highest expression was 
again seen in the body but high levels were also observed in the yolk sac (Figure 5). This is 
also true in Tracy mice where both the head and yolk sac have highest expression of the 
transgene (Figure 6).
Comparisons of transgene expression following either maternal or paternal 
transmission of the transgene were carried out in the Titus and Tilly lines and in each case 
















Figure 1. Constructs used in transient transfections and transgenics experiments.
The first column of letters and numbers represents construct name. The regions represented are: 
Differentially methylated region 1 (DMR1 red boxes), the Ig fl P3 promoter (orange boxes), luciferase 
reporter gene (yellow arrow), lacZ reporter gene (green arrow), position of HI 9 enhancers (blue circles) and 
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Figure 2: Luciferase levels of organ homogenates following either male or female transmission of the 
transgene in Eva mice at el4.5.
Organs represent parts of embryos analysed, and male and female columns represent male and female 
transmission o f the transgene. Results of Mann-Whitney analysis: Head P= 0.2 n/s, Body P= 0.7 n/s, Placenta 
P= 0.1 n/s, Yolk sac P= 0.7 n/s.
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Figure 3: Luciferase levels of organ homogenates following either male or female transmission of the 
transgene in Elvis el4.5 mice.
Organs represent parts of the embryo analysed and male and female columns represent male and female 
transmission of the transgene. Mann-Whitney analysis results: Head P= 1.0 n/s, Body P= 0.0057 n/s, Placenta 
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Figure 4: Luciferase levels of organ homogenates following both male and female transmission of the 
transgene in Titus el4.5 mice.
Organs represent parts o f the embryos analysed and male and female columns represent male and female 
transmission of the transgene. Mann-Whitney results: Head P=1 n/s, Body P=0.23 n/s, Placenta P= 0.4 n/s, 
Yolk sac Not enough samples.n=4
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Figure 5: Luciferase levels of organ homogenates following both male and female transmission of the 
transgene in Tilly el4.5 mice.
Organs represent parts o f the embryos analysed and male and female columns represent male and female 
transmission of the transgene. Mann-Whitney results: Head P= 0.057 n/s, Body P= 0.4 n/s, Placenta P= 
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Figure 6: Luciferase levels of organ homogenates following female transmission of the transgene in 
Tracy el4.5 mice.
Organs represent parts o f the embryos analysed female columns represent female transmission o f the 
transgene. n=3
4.2.1. Transgene expression of T and E constructs at e!4.5
Statistical analysis of the expression levels of all the T lines (Titus, Tilly and Tracy) 
compared with all the E lines (Eva and Elvis) showed significant differences in expression 
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Figure 7: graph representing luciferase levels of organ homogenates of both T and E expressing mouse 
lines at el4.5.
Constructs represent which luciferase construct the mice are expressing and columns represent body parts 
analysed. Mann-Whitney results of T vs. E: Head P= 0.0021 is significant. Body P= 0.012, Is significant. 
Placenta P= 0.218, n/sYolk sac P= 0.326 n/s.
4. 2.1.4 Transgene expression in Eva and Elvis lines at davl
Luciferase levels in the Eva and Elvis lines were measured when the mice were one day 
old. In the Eva mice luciferase expression was highest in the liver and lowest in the tongue. 
In the Elvis mice expression was highest in the tongue and lowest in the muscle. 
Comparisons of transgene expression following either maternal or paternal transmission of 
the transgene were carried out and no statistically significant differences were found. 
(Figure 8 and Figure 9).
4.2.1.5 Transgene expression in Titus, Tilly and Tracy lines at davl
There were no differences in transgene expression following male and female transmission 
of the transgenes where there were enough samples for statistical analysis to be carried out, 
in the Titus (Figure 10), Tracy (Figure 11) or Tilly (Figure 12) lines. Following female 
transmission of the transgene in the Titus mice, expression levels were highest in the 
muscle and lowest in the kidney and brain. Following male transmission of the transgene
86
expression was highest in the kidneys and lowest in muscle. In the Tracy mice highest 
expression following female transgene transmission was seen in the tongue and lowest 
expression was seen in the liver. Following male transgene transmission, highest 
expression was seen in the muscle and lowest expression was seen in the liver. In the Tilly 
mice follow ing female transmission of the transgene, expression levels were highest in the 
tongue and lowest in the liver.
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Figure 8:Luciferase levels of organ homogenates following either male or female transmission of the 
transgene in Eva dayl mice.
Organs represent parts of the embryos analysed and male and female columns represent male and female 
transmission of the transgene.
Mann-Whitney results: Brain P=1 n/s, Tongue P=4 n/s, Liver P= 1 n/s, Kidney P= 0.7 n/s, Muscle P 0.7 n/s


















0 .0 7 5 -
0 .0 5 0 -




m M  iS l _C^L
Brain Tongue Liver Kidney Muscle 
Organs
Figure 9: Luciferase levels of organ homogenates following either male or female transmission of the 
transgene in Elvis dayl mice.
Organs represent parts of the embryos analysed and male and female columns represent male and female 
transmission of the transgene. Mann-Whitney results: Brain P= 0.1 n/s, Tongue P= 0.9 n/s, Liver P= 0.23 n/s, 
Kidney P= 0.66 n/s, Muscle P=0.25 n/s.
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Figure 10: Luciferase levels of organ homogenates following both male and female transmission of the 
transgene in Titus dayl mice.
Organs represent parts of the embryos analysed and male and female columns represent male and female 
transmission of the transgene.
Mann-Whitney results: Brain P= 0.057 n/s, Tongue P= 0.114 n/s, Liver P= 0.342 n/s, Kidney P= 0.114 n/s, 
Muscle P= 0.485 n/s.
Figure 11
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Figure 11: Luciferase levels of organ homogenates following both male and female transmission of the 
transgene in Tracy dayl mice.
Organs represent parts of the embryos analysed and male and female columns represent male and female 
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Figure 12: Luciferase levels of organ homogenates following female transmission of the transgene in 
Tilly dayl mice.
Organs represent parts of the embryos analysed and female columns represent female transmission of the 
transgene.
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4.2.1.6 Transgene expression T and E lines at davl.
At dayl there is a significant difference in expression between the E and T lines of mice in 
the liver (Figure 13). There was no significant difference between the expression levels 












CD 0.5  c
1.03







Figure 13: graph representing luciferase levels of organ homogenates of T andE expressing lines at 
dayl.
Constructs represent constructs expressed and columns represent organs analysed.
Mann-Whitney analysis: Brain P= 0.063 n/s, Tongue P= 0.104 n/s, Liver P= 0.012 is significant.
Kidneys P= 0.554 n/s, Muscle P= 0.296 n/s.
4.2.2 Male verses female transgene transmission
In the summary of analysis (Table 1) of male versus female transmission at el 4.5 
there was higher female transgene expression in exactly half of the organs examined. Eva 
always had higher expression following female transmission, Elvis had mostly higher 
expression following male transmission, Titus was evenly divided between the sexes and 
Tilly had mostly higher expression levels following male transmission of the transgene. In 
the head expression was mostly higher from the female transgene, in the body there was 
mostly higher expression following male transmission and in the placenta and yolk sac is 
evenly split.
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Head Body Placenta Yolk sac
Eva ? ? ? 9
Elvis 0+ c? 3 3
Titus 3 3 2 2
Tilly 2 3 3 3
Table 1. Summary of relative levels of transgene expression fo [lowing male or fema e transmission at
el4.5.
Rows show transgenic mouse lines and columns show organs analysed. The symbols represent whether 
expression was higher following male (S )  or female ($ )  transmission.
At dayl (Table 2) the Eva lines had mostly higher expression following male 
transmission, Elvis had all higher expression following male transmission, Titus had 
mostly higher expression following male transmission and Tracy had mostly higher 
expression following female transmission.
In the brain expression was always higher when transmitted from the male transgene, in 
the tongue, liver and kidney it was mostly higher when transmitted from the male 
transgene and in the muscle it was mostly higher when transmitted from the female 
transgene.
Brain Tongue Liver Kidney Muscle
Eva 6 3 c? 2 2
Elvis (J 3 3 3 3
Titus <? 2 3 3 2
Tracy 6 2 2 2 2
dayl.
Rows show transgenic mouse lines and columns show organs analysed. The symbols represent whether 
expression was higher following male (d1) or female ($ )  transmission.
4.2.3Blots
Figure 14 shows a selection of southern blots carried out on the luciferase expressing 
organs. Genomic DNA was digested with Hpall which can only digest unmethylated DNA 
and also digested with MspI which can digest both methylated and unmethylated DNA.
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Elvis Body, e l4.5
9 3
B BH BM B BM BH
Eva Placenta, e l4.5
?
B BM BH B BM BH
t
m
Tilly e l4.5 Yolk sac
9 6
B BH BM B BH BM
Titus e l4.5 Yolk sac
<? 9
B BH BM B BH BM
Titus el4.5 head
3 9
B BH BM B BH BM
Figure 14: Sections of methylation sensitive blots of DNA from Elvis body, Eva placenta, Tilly yolk sac, 
Titus yolk sac and Titus head.
6  refers to male transgene transmission; 9 refers to female transgene transmission. B stands for BamHl 
digest, BH stands for a BamHl and H pall digest and BM stands for a BamHl and MspI digest. Red arrow 
indicates differences in band patterns between equivalent digests.
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4.3 LacZ transgenic mice:
4.4.1 C Construct
The first construct injected into embryos was C (Figure 15) which was generated by M. 
Charalambous who also genotyped all subsequent litters and all further analysis. However 
construct C was really only used as a reference construct and so no further comment on the 
results are made in this thesis, but can be found in (Charalambous 2004). A summary of 
the injections carried out can be found in the appendix. Two PCR positive mice were found 
but only one was discovered to transmit the transgene onto the next generation (Christian). 
Two other C mice were created by M. Charalambous called Cornelius and Columbo.
Below is a comparison of the expression patterns showed by these three transgenic mice.
Christian Columbo Cornelius
Choroid plexus S S
Meninges S S
Somite derivatives X X X
Tongue
Cartilage (ear and 
neck)
Table 3. Summary of expression patterns of the C transgene in the Christian, Columbo and Cornelius 
lines.
Cornelius, Christian and Columbus are transgenic mice expressing the C transgene. The ticks indicate those 





Figure 15: Comparison of LacZ staining in three lines of mice expressing the C construct at el2.5.
Blue areas are sites of transgene expression. The Christian line was generated by S. Kelly, and the Cornelius 
and Columbo lines were generated by M. Charalambous.
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4.3.2 D construct:
Construct D was created by M. Charalambous and two PCR positives were found when 
litters were genotyped. However no transgenic positive pups were found when these 
PCR+ve mice (Dave and Daphne) were mated so it possible that these mice were mosaic 
for the transgene and did not pass it on to their offspring. A summary of the numerous 
injections carried out can be found in the appendix. Dilutions of the transgene were tried 
but with no further success
One possibility is that the construct was toxic to the embryos. Litter sizes were 
consistently smaller than average, which sometimes led to the pups being destroyed and 
ingested by the mother. This happens if the energy that would have been expended by the 
mother in rearing the litter would out weigh the benefits of having a small litter.
4.3.3 F constructs:
One potential founder (named Fran) was identified when genotyped as PCR positive but 
subsequent mating did not produce a transgenic mouse line. Like Dave and Daphne, Fran 
did not pass the transgene onto the next generation and so was possibly mosaic. As no 
transgenic mice were forthcoming, from the 24/1/02 to the 21/3/03, the pseudopregnant 
mice were not allowed to go to term but the embryos were removed at e l4.5 and stained 
ioxLacZ. This resulted in two blue and therefore two transgenic mice (Figure 16). 
However no lines could be created, as the mice were still embryos when dissected. A 
summary of the injections carried out can be found in the appendix.
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Figurel6: Comparison of LacZ staining of transgenic mice Fa and Fb expressing construct F at el4.5.
Blue areas show sites of transgene expression. Cp shows the choroid plexus, T the tongue, NC nasal 
cartilage, G the gut, L the liver, S and SC the spinal column.
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4.3.4 Comparison between mice expressing construct F at e!4.5
Mice expressing construct F were sectioned and examined to determine the expression 




Nasal cartilage S S
Mid-forebrain S S




Table 4. Comparison between Fa and Fb transiently transgenic mice.
Fa and Fb are transgenic mice expressing construct F. The ticks indicate which organs express the transgene 
and the crosses indicate which organs did not express the transgene.
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4.4 Transient transfections:
Constructs M, T, A, E and Me-14 were transfected into HepG2 cells and luciferase 
expression levels were assayed (Figure 17). Construct A had the highest expression level,
T was the next highest closely followed by M. Constructs E and Me-14 were the lowest 
expressing constructs.
When these constructs were methylated in a separate series of transfections the 
expression levels changed (Figure 18). Luciferase levels are much lower in the second 
series of transfection than in the first series. Also, the unmethylated constructs were 
expected to behave as the unmethylated constructs in the first series of transfections, which 
they did not. Construct A did not have the highest luciferase level as it did initially, and 
which was the expected result. When methylated, construct Me-14 was the most highly 
expressed and construct A had the lowest expression level with statistical analysis showing 
no significant differences between methylated and unmethylated constructs.
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Figure 17




Figure 17. Luciferase levels of constructs transfected into HepG2 cells.
The letters on the X-axis represent the constructs transfected into the HepG2 cells. M has P3 promoter and 
the luciferase reporter gene, T had DMR1, P3 and luciferase, A had P3, Luciferase and the H19 enhancers, E 
had DMR1, P3, Luciferase and the HI9 enhancers and finally Me-14 had DMR1 with two added restriction 
sites (Aatll, Ndel  ^ p3  ^ luciferase and the H19 enhancers.
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Figure 18. Luciferase levels of unmethylated and methylated constructed transfected into HepG2 cells.
The letters on the X-axis represent the constructs transfected into the HepG2 cells. M has P3 promoter and 
the luciferase reporter gene, T had DMR1, P3 and luciferase, A had P3, Luciferase and the H19 enhancers, E 
had DMR1, P3, Luciferase and the H19 enhancers and finally M e-14 had DMR1 with two added restriction 
sites (Aatll Ndel  ^ p3 ; luciferase and the H19 enhancers.
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Discussion:
Chapter Four: Analysis of DMR1 in transgenic mice and in transient transfections.
Analysis of transgenic mice expressing luciferase reporter gene and injection of embryos of 
mice with LacZ reporter gene to analyse elements of Igf2/H19 gene region.
4.0 Analysis of Eva and Elvis transgenic mice.
When assayed Eva and Elvis lines were compared at e l4.5 there were differences in relative 
expression levels in the organs. Eva had highest expression in the body and Elvis had highest 
expression in the head. Even though both lines were injected with the same construct the 
transgene enters the genome in random positions and the differences in expression levels 
between Eva and Elvis could be due to positional effects or due to transgene copy number. 
The genomic elements surrounding the site of transgene integration may have inhibitory 
effects on the luciferase gene. Both lines have higher expression in the embryo than in the 
extra embryonic tissues. This implies that DMR1, P3 and the H I9 enhancers are more active 
in the embryo than in the yolk sac and placenta. H I9 enhancers are known to increase 
transgene expression levels 10-20-fold in the brain (Ward 1997), which could explain the 
higher transmission in the embryo than detected in the extra embryonic tissues.
In the dayl samples expression was highest in the liver in Eva and highest in the 
tongue in Elvis mice. This correlates with the results found at e l4.5. The transgene shows 
increased expression in the body at el4.5 of Eva mice and the liver at day l. It is possible that 
in the body homogenates it is primarily the liver that increases expression levels and this 
becomes apparent in the more detailed dissections carried out at day 1. This could also be true 
for the Elvis mice with the expression in the tongue being responsible for the high expression 
levels found in the head homogenates at el 4.5. The enhancer activity of HI 9 enhancers in the 
liver was demonstrated previously (Ward 1997) with the addition of HI 9 enhancers 
increasing transgene expression many thousand fold when E and T lines were compared. This 
was maintained in the liver up to 4 days postnatally.
Methylation sensitive blots carried out on samples from Elvis and Eva mice 
showed methylation differences in Elvis e l4.5 $ body between lane two and three. There was 
an extra band in the MspI lane where the enzyme digested the DNA where the Hpall could 
not due to methylation. This methylation occurred in the maternally transgene transmitted 
sample and not in the paternally transmitted sample, but as shown in Figure 3. there was 
higher transmission from the paternally expressed transgene. It appears that the methylation 
of the maternally expressed transgene down regulated expression but not to a statistically
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significant extent. There were no methylation differences in the Eva e l4.5 blots, which 
correlated with there being no differences in luciferase expression following male and female 
transmission of the transgene.
4.1 Analysis of Titus, Tilly and Tracy transgenic mice
In the three T lines at e l4.5 the highest luciferase expression was observed in the body of 
Titus mice, body and yolk sac of Tilly mice and head and yolk sac of Tracy mice. Construct T 
has DMR1, P3 and the luciferase reporter gene. In most of the T mice, both the embryo and 
the extra embryonic tissue have high luciferase levels. It could be the case that the H19 
enhancers present in the E lines up-regulated expression in the embryo but not in the extra- 
embryonic tissues so that in the T lines expression levels between the embryo and the extra 
embryonic tissues are comparable. Also expression levels are much higher in the E lines than 
in the T lines, consistent with the presence of the HI 9 enhancers in the E transgene.
At dayl it was in the kidney that expression was highest in Titus mice, and in the 
tongue, expression was lowest. This agrees with what was observed at e l4.5 with the more 
detailed dissection carried out at day one revealing the kidney as one possible source of high 
expression in the body homogenate. In Tracy mice expression was highest in the tongue and 
lowest in the brain, which again agrees with the data at e l4.5, with tongue contributing to 
high transgene expression in the head. In Tilly mice, expression was highest in the tongue and 
lowest in the brain. This does not correlate with the observation at e l4.5 as the liver, kidney 
and muscle had quite low levels of expression individually yet the body homogenate at el 4.5 
showed much higher expression levels. This could be due to a different organ in the body 
region having very high luciferase expression. Previously it was shown that DMR1 decreased 
transgene activity in the liver and brain, which correlates with findings in this study (Ward 
1997).
The results of the methylation sensitive blots showed no methylation 
differences in the Tilly el4.5 yolk sacs, Titus el4.5 yolk sacs and Titus el4.5 heads.
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4.2 Comparison between construct T and construct E.
The E lines had higher expression than the T lines at e l4.5 which is not surprising given that 
both transgene constructs contain DMR1 and Ig£2 P3, but construct E also contains the HI 9 
enhancers which are known to increase expression levels of Igf2.
It appears that expression is significantly higher in the embryo than it is in the extra 
embryonic tissues at e l4.5 in the Eva and Elvis mice so it appears that the addition of H19 
enhancers does not effect expression of Igf2 in the placenta and yolk sac.
This result also occurred at dayl with E mice having significantly higher levels of 
expression than T mice, but only in the liver. Expression levels were similar in all of the other 
organs. This correlates with previous findings (Ward 1997) that showed high expression from 
construct E in the liver and that the H19 enhancers are mostly active in endodermally derived 
tissues.
4.3 Comparison between male and female transmission of the transqenes
There were no statistically significant differences, in any comparison made following male 
and female transmission of the transgene.
In Eva e l4.5 pups however expression was always highest following female 
transmission but at day one this fell to only being highest in the kidney and muscle. It may 
have been expected that luciferase levels would be highest following male transmission of the 
transgene due to paternal methylation of DMR1, leading to up-regulation of the transgene, as 
occurs in the paternal allele of endogenous Igf2. The Elvis mice followed this expectation 
more closely with higher expression occurring in all organs except for the head at e l4.5 
following paternal transmission of the transgene.
Similarly, the Titus mice had higher expression following paternal transgene 
transmission in 5 out of the 9 organs analysed. Luciferase levels were generally very low in 
the T lines, however in Tilly mice at el4.5 there was mostly higher expression from the 
paternally inherited transgene except for in the head, but in the Tracy day 1 sample there was 
mostly higher expression levels following maternal transmission of the transgene. Liver and 
brain analysis carried out on transgenic mice with paternal transmission of the transgene 
showed high expression from E lines of mice and low expression from T lines of mice (Ward 
1997). When paternal and maternal transmission of the transgene was compared, E lines of 
mice showed higher expression levels when paternally expressed and T lines of mice showed 
higher expression levels when maternally expressed.
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5.0 Analysis of LacZ transgenic mice
5.1 Transgenic mice expressing construct C
One C mouse was created which was named Christian. When compared with the C mice 
created by M. Charalambous the expression patterns were found to be similar. When 
compared to each other (Charalambous 2004), common sites of expression were the 
leptomeninges, choroid plexus, lens of the eye, tongue, mesenchyme of the head, tubules of 
the ear and the ureter. Differences between the three C lines were seen in the abdominal wall 
muscle where only Colombo mice showed expression, facial ganglia, dorsal root ganglia and 
peripheral (to the mesonephros) ganglia where only Cornelius mice showed expression, and 
in the digital cartilage and dermis of the skin where only Christian mice showed transgene 
expression. The sites of differential transgene expression could be due to positional effects as 
the transgene probably inserted into different regions of the mouse genome in each of the 
three C lines.
5.2 Transgenic mice expressing construct F
Two F e 14.5 transgenic mice were also created which also had similar patterns of 
expression as each other. Sites of common expression at e l4.5 between mouse Fa and mouse 
Fb were the choroid plexus, nasal cartilage, rib bones, mid-forebrain, spinal column and the 
intestines. Sites of differential expression were the tongue muscle where only mouse Fa 
showed transgene expression, the meninges surrounding the spinal column where only mouse 
Fa showed transgene expression, the heart where there is only visible expression from mouse 
Fa and the liver where only mouse Fa showed transgene expression. All of these regions are 
derived from the mesoderm and endoderm, which means that it is possible that in mouse Fb 
the transgene inserted near to a meso/endodermal silencer.
5.3 Comparison of C transgenic mice with F transgenic mice.
When compared to each other the C and F lines have common sites of expression such 
as the choroid plexus, tongue (except for Fb), some cartilage and the meninges (except for 
Fb). Differences in sites of expression can be seen in the lens of the eye where there is no F 
transgene expression visible and in the intestines where there appears to be little or no C 
transgene expression. The difference between construct C and construct F is that construct C 
had the CCD as well as P3 and LacZ reporter gene and construct F has DMR1 as well as P3 
and LacZ reporter gene. The presence of CCD leads to transgene expression in more areas of 
the brain than shown by construct F and to less expression in the abdomen and the organs 
within.
104
The presence of DMR1 on construct F leads to more mesodermal and endodermal 
organs expressing the transgene. It is thought that the CCD acts as an enhancer for Igf2 
expression in the brain (Ainscough 2000) where Igf2 is biallelically expressed and that DMR1 
exerts control over Igf2 expression in mesodermal tissues as a maternal deletion of DMR1 
leads to biallelic expression of Igf2 in mesodermal tissues (Constancia 2000).
The differences in transgene expression between the two lines of mice agree with previous 
findings regarding the roles of CCD and DMR1 in controlling Igf2 expression.
6.0 Transient transfections
The results of transient transfection carried out in HepG2 cells are shown in Figure 17. 
Construct A had the highest expression levels which agrees with transgenic analysis previous 
carried out (Ward 1997) which showed that transgenic mice expressing construct A had the 
highest levels of expression. This is due to the construct containing HI 9 enhancers and not 
experiencing the silencer activity of DMR1. Construct T had the next highest level of 
expression which correlates with previous work where construct T when expressed in the 
kidney showed lower expression than A and higher expression than M, which is also true in 
this study. Constructs E and Me-14 had the lowest expression levels despite the presence of 
H I9 enhancers showing an inhibitory effect of DMR1.
These constructs were methylated and the result was a reversal in expression levels 
with construct A now having the lowest expression level and Me-14 having the highest. 
Construct A does not contain DMR1 and construct Me-14 does contain DMR1 which as 
previously shown, methylated DMR1 up regulates gene expression (Li, Beard et al. 1993). 
Expression levels of construct T (DMR1 present) remained higher than construct M (no 
DMR1 present). Construct E would have been expected to demonstrate the same increase in 
expression as construct Me-14, but expression from construct E was lowest of all the 




In Chapter three the aim was to determine if:
1. Deletion of DMR1 resulted in a different tumour spectrum than had been observed in 
previous experiments carried out on p53 knockout mice?
The tumour spectrum in this study was not significantly different from previous observations. 
These DMR1 knockout/p53knockout mice typically showed tumours of the thymus, lymph 
nodes and spleen which aggress with mice analysed which were p53knockout only.
2. Do tumours develop sooner or later than had been previously observed?
Tumours did not occur sooner or later in DMRlknockout/p53 knockout mice than occurred in 
p53knockout mice. Altering DMR1 status did not result in a shorter or longer life span for 
these mice and tumour development did not occur earlier or later in development.
3. Does a deletion of DMR1 result in heavier or lighter mice?
Deletion of DMR1 results in prolonged postnatal expression of Igf2. It appears that at 4 weeks 
wtDMRl mice were the heaviest with the prolonged higher levels of circulating Igf2 not 
resulting in heavier mice. However at 8 weeks, prolonged Igf2 expression in paternal 
deletions of DMR1 resulted in heavier than wild type mice. This result had disappeared at 9- 
10 months of ages indicating that Igf2 levels had reverted to normal levels.
Wild type mice were shown to have the heaviest organs, the highest percentages of body fat, 
the steepest growth curves and the most visible glycogen in the liver sections.
The aims of chapter four were to determine if:
4. Analysis of the function of elements present on H19/Igf2 gene region both In vitro and 
In vivo?
In transgenic mice expressing constructs with H19 enhancers, expression is upregulated 
in both extra embryonic and embryonic tissues, but expression is significantly higher in the 
embryo than in the placenta and yolk sac. H19 enhancers have a less upregulatory effect in 
the extra embryonic tissues.
5. Were there any differences between male and female transmission of transgenes?
There were no significant differences between male and female transmission of trangenes 
which is not surprising considering none of the construct contained the ICR which sets the 
imprint for this gene region and without it imprinting marks do not follow endogenous 
patterns of expression. Also there were no differences in methylation in these mice.
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6. In which organs was expression found to be the highest?
In the liver, luciferase expression was found to be highest when the H I9 enhancers were 




1.1 Injections carried out with transgene C.
Table 1. summarises the injections carried out with construct C over a period of four 
months. Table 2. summarises injections carried out over a period of 2 years using 
transgene construct D. On the 14/6/00 to the 1/6/00 the embryonic transfers were 
carried out by me but resulted in no pups being bom. Also different concentrations of 
the transgene were injected on the 18/7/02, 25/7/02 and 22/8/02. These lower 
concentrations did not yield transgenic mice. Table 3 summarises injections carried 
out over a period of 2 years using construct F. From the 28/6/01 to the 20/12/01 half 
of the embryonic transfers were carried out by A. Ward and half by S. Kelly. From 
the 24/1/02 to the 21/3/03 the pseudopregnant mice were not allowed to go to term 
but the embryos were removed at E14.5 and stained for LacZ. This resulted in two 
blue and therefore two transgenic mice. However no lines could be created, as the 
mice were still embryos when dissected.
Injection date No. injected DOB No. born Analysis
12/4/00 25 embryos 1/5/00 4 All -ve
15/5/00 28 embryos 29/5/00 3 All -ve
24/5/00 56 embryos 13/6/00 10 All -ve
31/5/00 28 embryos None bom 0
6/7/00 60 embryos 25/7/00 10 1 PCR +ve
19/7/00 37 embryos None bom 0
17/8/00 50 embryos 5/9/00 8 All -ve
31/8/00 45 embryos 19/9/00 7 1 PCR +ve
Table 1. Summary of injections carried out with transgene construct C.
The injection date refers to the date the embryos were injected with construct C and the No. Injected 
refers to how many embryos were injected. DOB indicates the date o f birth o f any subsequent pups and 
No. bom indicates how many pups were in that litter. The Analysis column indicates the results when 
the pups were genotyped, All-ve meaning that all the pups were PCR negative, and +ve indicates how 
many were PCR positive for the transgene.
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Injection date No. injected DOB No. born Analysis
7/9/00 45 None bom 0
14/9/00 43 3/10/00 7 All -ve
21/9/00 54 None bom 0
28/9/00 32 17/10/00 13 All -ve
5/10/00 52* 25/10/00 4 1 PCR +ve (Dave)
12/ 10/00 43 1/ 11/00 2 1 PCR+ve (Daphne)
26/10/00 32* None bom 0
2/ 11/00 40* None bom 0
16/11/00 34* None bom 0
24/11/00 30 None bom 0
7/12/00 40* None bom 0
14/12/00 39* None bom 0
21/6/00 33 None bom 0
14/6/00 50* 4/7/02 2 All -ve
7/6/00 40* None bom 0
1/6/00 50* None bom 0
21/6/00 33 None bom 0
8/2/02 50 None bom 0
22/2/02 22 None bom 0
23/5/02 38 None bom 0
18/7/02 25 (1/10) None bom 0
25/7/02 45 (1/10) None bom 0
22/8/02 50 (1/50) 11/0/02 7 All -ve
12/9/02 25 None bom 0
17/10/02 30 None bom 0
14/11/02 32 None bom 0
Table 2. Summary of injections carried out with transgene construct D.
The injection date refers to the date the embryos were injected with construct D and the No. Injected 
refers to how many embryos were injected. DOB indicates the date o f birth o f any subsequent pups and 
No. bom indicates how many pups were in that litter. The Analysis column indicates the results when 
the pups were genotyped, All-ve meaning that all the pups were PCR negative, and +ve indicates how 
many were PCR positive for the transgene. The astirex indicate when surgery was carried out by S. 
Kelly. The numbers in brackets indicate the dilution of the transgene injected.
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Injection date No. injected DOB No. born Analysis
28/6/01 55* 17/7/01 7 1 PCR +ve(Fran)
5/7/01 66* None bom 0
12/7/01 45* 31/7/01 7 All -ve
19/7/01 40* None bom 0
6/9/01 55* None bom 0
13/9/01 43* None bom 0
20/9/01 76* 10/ 10/01 7 All -ve
27/9/01 25* None bom 0
4/10/01 50* None bom 0
11/ 10/01 60* None bom 0
18/10/01 72* 6/ 11/01 3 All -ve
22/11/01 38* 10/ 12/01 4 All -ve
29/11/01 44 (1/3) * None bom 0
7/12/01 36 (1/3)* None bom 0
20/12/01 53 (1/3)* 8/ 1/02 7 All -ve
18/1/02 18 None bom 0
24/1/02 58 None bom 0
7/2/02 60 None bom 0
14/2/02 55 None bom 0
21/2/02 41 None bom 0
28/2/02 30 20/3/02 3 All -ve
14/3/02 50 3/4/02 5 All -ve
28/3/02 25 None bom 0
16/5/02 33 4/6/02 5 All -ve
30/5/02 50 None bom 0
13/6/02 47 None bom 0
13/12/02 33 None bom 0
24/1/02 30 (transient) 7/2/02 dissect 2 2 PCR +ve
30/1/02 21 (transient) None Found 0
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6/2/02 50 (transient) 21/2/02 dissects 2 All -ve
20/2/02 51 (transient) None found 0
27/2/03 40 (transient) 14/3/03 dissects. 1 All -ve
12/3/03 46 (transient) 27/3/03 dissects. 3 All -ve
6/3/03 62 (transient) 21/3/03 dissects. 7 All -ve
21/3/03 30 (transient) None found 0
Table 3. Summary of injections carried out with transgene construct F.
The injection date refers to the date the embryos were injected with construct F and the No. Injected 
refers to how many embryos were injected. DOB indicates the date of birth o f any subsequent pups and 
No. bom indicates how many pups were in that litter. The Analysis column indicates the results when 
the pups were genotyped, All-ve meaning that all the pups were PCR negative, and +ve indicates how 
many were PCR positive for the transgene. The asterix indicate when surgery was carried out by S. 
Kelly. The numbers in brackets indicate the dilution of the transgene injected.
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